| Details |
title |
year |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-484 PROSPECTIVE STUDY TO ASSESS LONG-TERM OUTCOMES OF TREATMENT WITH TR... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-285 ADIPOSE TISSUE INSULIN RESISTANCE IS ASSOCIATED WITH MACROPHAGE ACT... |
2016 |
| Details |
FRI-051 EFFICACY OF AKT INHIBITOR ARQ 092 COMPARED WITH SORAFENIB IN A CIRR... |
2016 |
| Details |
SAT-019 REVERSAL OF TYPE I HEPATO-RENAL SYNDROME WITH TERLIPRESSIN AND OCTR... |
2016 |
| Details |
SAT-114 SIGNIFICANT REDUCTIONS IN COSTS OF GENERIC PRODUCTION OF SOFOSBUVIR... |
2016 |
| Details |
PS124 EFFICACY AND SAFETY OF INDUCTION DOSING OF VEDOLIZUMAB FOR REDUCING B... |
2016 |
| Details |
THU-485 RETROSPECTIVE STUDY TO ASSESS LONG-TERM OUTCOMES OF CHELATOR-BASED ... |
2016 |
| Details |
THU-181 EFFECT OF THE HEPATITIS B CORE PROTEIN C-TERMINAL DOMAIN MUTATIONS ... |
2016 |
| Details |
FRI-286 ANGIOPOIETIN-LIKE4 IS ASSOCIATED WITH LIPID METABOLISM AND SEVERE F... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-020 TERLIPRESSIN-INDUCED HYPONATREMIA IN CIRRHOTIC PATIENTS WITH VARICE... |
2016 |
| Details |
SAT-115 INTEGRATED, CO-LOCATED, TELEMEDICINE-BASED TREATMENT APPROACHES FOR... |
2016 |
| Details |
PS125 SEROLOGICAL BIOMARKERS OF EXTRACELLULAR MATRIX REMODELING PREDICT TRA... |
2016 |
| Details |
THU-486 PRO-EURO-DILI REGISTRY: A COLLABORATIVE EFFORT TO ENHANCE THE UNDER... |
2016 |
| Details |
THU-182 HBV E ANTIGEN AND ITS PRECURSORS PROMOTE THE PROGRESS OF HCC BY INT... |
2016 |
| Details |
HISTOPATHOLOGICAL ASPECTS... |
2016 |
| Details |
FRI-052 THE MACROPHAGE PROTEIN CD5L ACTS AS A PRO-ONCOGENIC FACTOR IN HEPAT... |
2016 |
| Details |
SAT-021 NORFLOXACIN ESTIMULATES TREG-MEDIATED MODULATION OF PROINFLAMMATORY... |
2016 |
| Details |
SAT-116 COMORBIDITIES, COMEDICATION AND POTENTIAL DRUG TO DRUG INTERACTIONS... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-487 A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE- AND MULTIPLE-DOSE, D... |
2016 |
| Details |
THU-183 EXPLORING CURRENT HEPATITIS B VIRUS THERAPIES IN SINGLE AND COMBINA... |
2016 |
| Details |
CHANGES IN FGF15/19 EXPRESSION AND BILE ACID LEVELS AS SENSITIVE MARKERS O... |
2016 |
| Details |
RECEPTOR I KINASE INHIBITOR, GALUNISERTIB (LY2157299) INHIBITS HEPATOCELLU... |
2016 |
| Details |
SAT-022 SELF-REPORTED QUALITY OF LIFE IN PATIENTS TREATED WITH COVERED TRAN... |
2016 |
| Details |
SAT-117 COMORBIDITIES, RESOURCE UTILIZATION AND HEALTH CARE COSTS OF PATIEN... |
2016 |
| Details |
PS126 VALIDATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC SCORING SYSTEMS IN P... |
2016 |
| Details |
THU-488 REGENERATE: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-023 ASSESSING THE BLEEDING RISK AFTER LIVER BIOPSY USING NEW CLINICAL A... |
2016 |
| Details |
S) FOR CHRONIC HEPATITIS C IN A UNITED STATES TREATMENT COHORT... |
2016 |
| Details |
PS127 FIBROSCAN AND MRI HA VE COMPLEMENTARY PROGNOSTIC VALUES IN PRIMARY SC... |
2016 |
| Details |
THU-489 A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND... |
2016 |
| Details |
THU-184 BI- AND TRISPECIFIC ANTIBODYCONSTRUCTS MEDIATE SPECIFIC T- CELL RET... |
2016 |
| Details |
FRI-289 A NON-INVASIVE LIPIDOMIC TEST ACCURATELY DISCRIMINATES NON-ALCOHOLI... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-024 VASOACTIVE DRUGS FOR HEPATORENAL SYNDROME: A META- ANALYSIS... |
2016 |
| Details |
SAT-119 HIGH EFFICACY OF LEDIPASVIR/SOFOSBUVIR PLUS RIBA VIRIN AMONG PATIEN... |
2016 |
| Details |
PS128 EFFECTS OF PLASMAPHERESIS ON PRURITUS IN PATIENTS WITH PBC: PROSPECTI... |
2016 |
| Details |
THU-429 LIVER TRANSPLANTATION FOR CHILDREN WITH ACUTE LIVER FAILURE ASSOCIA... |
2016 |
| Details |
THU-185 CHARACTERIZATION AND FUNCTIONAL MODULATION OF HBV- SPECIFIC CD4+ T ... |
2016 |
| Details |
FRI-290 EXERCISE THERAPY IN PATIENTS CONSUMING MODERATE ALCOHOL: A RANDOMIS... |
2016 |
| Details |
FRI-054 SUMOYLATION CONTROLS THE LOCALIZATION AND ACTIVITY OF LKB1 IN LIVER... |
2016 |
| Details |
SAT-025 INCREASED BIOMARKERS OF CELL DEATH ARE ASSOCIATED WITH DEVELOPMENT ... |
2016 |
| Details |
SAT-120 OMBITASVIR/PARITAPREVIR/RITONA VIR + DASABUVIR + RIBA VIRIN (3D + R... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-430 DIAGNOSTIC ALGORITHM FOR HIGH LIVER IRON OVERLOAD: RESULTS FROM A P... |
2016 |
| Details |
THU-186 SCREENING AN FDA-APPROVED DRUG LIBRARY ON A CELL LINE THAT SUPPORTS... |
2016 |
| Details |
FRI-291 PREDICTING FATTY LIVER DISEASE IN HEALTHY POTENTIAL LIVER DONORS... |
2016 |
| Details |
FRI-055 TREATMENTS OF EXPERIMENTAL HEPATOCELLULAR CARCINOMA USING A NOVEL E... |
2016 |
| Details |
SAT-026 LOW MOLECULAR WEIGHT HEPARIN TREATMENT DOES NOT INCREASE THE RISK O... |
2016 |
| Details |
SAT-121 WEIGHT GAIN AFTER IFN-FREE CURE OF CHRONIC HEPATITIS C: A POTENTIAL... |
2016 |
| Details |
PS129 THE DYNAMICS OF FAST- AND SLOW- CYCLING STEM CELLS IN LIVER HOMEOSTAS... |
2016 |
| Details |
THU-431 SUCCESSFUL TREATMENT WITH 4-PHENYLBUTYRATE WITH RIFAMPICINE REFRACT... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-292 IMPACT OF CONTINUOUS POSITIVE AIRWAY PRESSURE TREATMENT ON NON-ALCO... |
2016 |
| Details |
FRI-057 CROSSTALK BETWEEN TGF-B AND EGFR PATHWAYS IN THE REGULATION OF HEPA... |
2016 |
| Details |
SAT-028 SELECTIVE INTESTINAL DECONTAMINATION WITH NORFLOXACIN IS ASSOCIATED... |
2016 |
| Details |
SAT-122 CAN WE CONTINUE AFTER LIVER TRANSPLANTATION WITH HCV TREATMENT STAR... |
2016 |
| Details |
PS130 INDUCED PLURIPOTENT STEM CELLS (IPSCS) DERIVED HEPATOCYTES FUNCTION I... |
2016 |
| Details |
THU-432 THERAPEUTIC EFFICACY OF TRIENTINE NANOPARTICLES IN WISTAR RAT MODEL... |
2016 |
| Details |
THU-187 THE HBX-DLEU2 LNCRNA COMPLEX REGULATES TRANSCRIPTION FROM THE HBV C... |
2016 |
| Details |
FRI-293 DEVELOPMENT AND VALIDATION OF A NON-INVASIVE MODEL FOR PREDICTING F... |
2016 |
| Details |
FRI-058 MIR-21 AND MIR-150 DOWNREGULATION IS ASSOCIATED WITH OXALIPLATIN-RE... |
2016 |
| Details |
SAT-029 EVALUATION AND IMPROVEMENT OF BA VENO 6 RECOMMENDATION FOR NON-INVA... |
2016 |
| Details |
SAT-123 TREATMENT OF HCV WITH SIMEPREVIR ASSOCIATED TO DACLATASVIR IN PATIE... |
2016 |
| Details |
PS131 ALTERED LIVER REGENERATION AFTER PARTIAL HEPATECTOMY IN PML-KNOCKOUT ... |
2016 |
| Details |
THU-433 INHIBITION OF THE CA2+-INHIBITED ADENYLYL CYCLASE 5 REDUCES CYST GR... |
2016 |
| Details |
THU-188 PARTIALLY RESTORED T CELL RESPONSES IN HBEAG-NEGATIVE CHRONIC PATIE... |
2016 |
| Details |
FRI-294 RELATIONSHIP BETWEEN PATTERN OF HEPATIC IRON DEPOSITION, DISEASE SE... |
2016 |
| Details |
FRI-059 NUCLEAR LOCALIZATION OF IMPDH2, THE PRIMARY TARGET OF MYCOPHENOLIC ... |
2016 |
| Details |
SAT-030 FREQUENCY OF RESISTANCE TO COMMONLY USED ANTIBIOTICS AMONG A GERMAN... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
PS132 NONINVASIVE IDENTIFICATION OF HEPATOCELLULAR CARCINOMA MUTATIONS IN P... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-189 HEPATITIS E VIRUS ORF3 PROTEIN FORMS MEMBRANE- ASSOCIATED OLIGOMERS... |
2016 |
| Details |
FRI-295 DETERMINATION OF A NORMAL VALUE FOR HOMA-IR AND CUT-OFF VALUE FOR N... |
2016 |
| Details |
FRI-060 HEPATOCELLULAR CARCINOMA DIFFERENTIALLY MODULATES AMPK ACTIVITY AND... |
2016 |
| Details |
SAT-031 CIRRHOTIC PATIENTS WITH TLR-9 RS187084 POLYMORPHISM DO NOT INCREASE... |
2016 |
| Details |
SAT-124 REAL LIFE EXPERIENCE IN TREATING CHRONIC HEPATITIS C WITH DIRECT AC... |
2016 |
| Details |
PS133 FUELING CELLULAR DIVISION DURING LIVER REGENERATION: CDK1 REGULATES E... |
2016 |
| Details |
THU-434 IN VITRO STUDY OF NOVEL COMPOUNDS TO TREAT FAMILIAL AMYLOID POLYNEU... |
2016 |
| Details |
THU-190 SINGLE CELL ANALYSES DEMONSTRATE NO UP-REGULATION OF HUMAN INNATE G... |
2016 |
| Details |
FRI-296 PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE AND FIBROSIS IN A L... |
2016 |
| Details |
FRI-061 STANNIOCALCIN 1 OVEREXPRESSION PROMOTES METASTASIS IN HEPATOCELLULA... |
2016 |
| Details |
SAT-032 URINARY BIOMARKER NGAL IN PATIENTS WITH CIRRHOSIS AND BACTERIAL INF... |
2016 |
| Details |
A PROOF OF CONCEPT TRIAL OF TG-2349 (FURAPREVIR)... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-297 QUANTIFICATION OF LIVER STEATOSIS USING THE NEW SCORE ULTRASOUND FL... |
2016 |
| Details |
FRI-062 INFLAMMATION AND FIBROSIS IN THE LIVERS OF TNFR1/MDR2KO MICE... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-126 HIGH SVR12 RATES WITH COMBINATION OF NS5A- AND NS5B- INHIBITORS FOR... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
THU-436 ACCUMULATION OF HEPATITIS B SURFACE ANTIGEN PROMOTES THE DEVELOPMEN... |
2016 |
| Details |
THU-191 SIMILAR FREQUENCIES, PHENOTYPE AND ACTIVATION STATUS OF INTRAHEPATI... |
2016 |
| Details |
FRI-298 PREDICTORS OF LATE RECURRENCE AFTER LIVER RESECTION FOR HEPATOCELLU... |
2016 |
| Details |
FRI-064 REGULATION OF P53 FAMILY GENE EXPRESION AND AKT/JNK CELL SIGNALING ... |
2016 |
| Details |
SAT-033 URINARY BIOMARKER NGAL IN PATIENTS WITH HEPATORENAL SYNDROME: ACCUR... |
2016 |
| Details |
-EXPERIENCE WITH 2ND GENERATION DIRECTACTING ANTIVIRAL (DAA) TREATMENT IN H... |
2016 |
| Details |
PS134 GENERATION OF 3D HEPATIC STRUCTURE USING INDUCED HEPATOCYTE-LIKE CELL... |
2016 |
| Details |
THU-437 BENEFIT OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LYSOSOMAL AC... |
2016 |
| Details |
THU-192 INNATE IMMUNE SENSING OF HEPATITIS B VIRUS AND RESPONSE TO INTERFER... |
2016 |
| Details |
FRI-299 STEATOMETER: A NEW ULTRASOUND IMAGING SYSTEM FOR NON INVASIVE, NON-... |
2016 |
| Details |
FRI-065 SOX17 REGULATES CHOLANGIOCYTE DIFFERENTIATION AND ACTS AS A TUMOUR ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-128 C-EDGE IBLD: EFFICACY AND SAFETY OF ELBASVIR/GRAZOPREVIR (EBR/GZR) ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-438 URSODEOXYCHOLIC ACID IN ADVANCED POLYCYSTIC LIVER DISEASE: A MULTIC... |
2016 |
| Details |
THU-193 DIFFERENTIAL REDUCTIONS IN VIRAL ANTIGENS EXPRESSED FROM CCCDNAVS I... |
2016 |
| Details |
FRI-300 ENDOSCOPIC DUODENAL MUCOSAL RESURFACING (DMR) IMPROVES METABOLIC ME... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-034 INCIDENCE, PREDICTORS AND OUTCOME OF ACUTE KIDNEY INJURY IN PATIENT... |
2016 |
| Details |
SAT-129 DACLATASVIR PLUS SOFOSBUVIR PLUS RIBA VIRIN FOR 12 OR 16 WEEKS IN T... |
2016 |
| Details |
PS135 MIR-873 PROMOTES LIVER DE-DIFFERENTIATION AND FIBROSIS TARGETING GLYC... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-194 QUANTIFICATION OF HEPATITIS B CORE-RELATED ANTIGEN IS MORE USEFUL T... |
2016 |
| Details |
FRI-301 EFFECTS OF ORAL HIGH-DOSE VITAMIN D SUPPLEMENTATION ON NON-ALCOHOLI... |
2016 |
| Details |
FRI-066 MULTI-OMICS LANDSCAPE OF PRECANCEROUS LIVER DISEASE... |
2016 |
| Details |
SAT-037 MID-INFRARED SPECTROSCOPY HAS A HIGH SENSITIVITY AND SPECIFICITY FO... |
2016 |
| Details |
SAT-130 EFFICACY AND TOLERABILITY OF SIMEPREVIR AND DACLATASVIR FOR 12 OR 2... |
2016 |
| Details |
PS136 B1 INTEGRIN LOSS SWITCHES HEPATOCYTE REGENERATION FROM HEPATOCELLULAR... |
2016 |
| Details |
THU-439 POLYCYSTIC LIVER DISEASE PATIENTS WITH UNDERLYING DIAGNOSIS OF POLY... |
2016 |
| Details |
THU-195 HEPATITIS DELTAVIRUS EVOLUTION RATE IS HIGH IN PATIENTS WITH CHRONI... |
2016 |
| Details |
FRI-302 SHARED GENE EFFECTS BETWEEN HEPATIC STEATOSIS AND FIBROSIS: A PROSP... |
2016 |
| Details |
FRI-067 COMBINATION OF 4-METHYLUMBELLIFERONE AND ADENOVIRAL GENE TRANSFER O... |
2016 |
| Details |
SAT-038 CHANGES IN MICROBIOLOGICAL FLORA CAUSING SPONTANEOUS BACTERIAL PERI... |
2016 |
| Details |
SAT-131 SUSTAINED VIROLOGIC RESPONSE TO DACLATASVIR AND SOFOSBUVIR, WITH OR... |
2016 |
| Details |
PS137 HEPATITIS B SEROPREVALENCE AND IMMUNIZATION STATUS OF REFUGEES SEEKIN... |
2016 |
| Details |
THU-440 VALIDITY OF NON-INVASIVE FIBROSIS SCORES IN A LARGE COHORT OF PAEDI... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-303 NON-INVASIVE TESTS FOR THE DIAGNOSIS OF LIVER FIBROSIS ARE ALSO PRO... |
2016 |
| Details |
FRI-068 IMPACT OF CANCER STEM CELL-ASSOCIATED MACROPHAGES ON CHOLANGIOCARCI... |
2016 |
| Details |
SAT-039 INCIDENCE, PREDICTORS AND OUTCOMES OF ACUTE ON CHRONIC LIVER FAILUR... |
2016 |
| Details |
SAT-132 FAILURE TO FIRST-LINE DIRECT ANTIVIRAL (DAA) TREATMENT OF HCV INFEC... |
2016 |
| Details |
PS138 HIGH MORTALITY IN CHRONIC HEPATITIS C PATIENTS IN SWEDEN COMPARED TO ... |
2016 |
| Details |
THU-441 INDUCED PLURIPOTENT STEM CELLS (IPSCS) FROM A PATIENT WITH FAMILIAL... |
2016 |
| Details |
THU-196 TOLL-LIKE RECEPTOR 4 PATHWAY MEDIATE LIVER FIBROSIS IN CHIMERIC MIC... |
2016 |
| Details |
FRI-304 NOVEL SERUM LIPIDOMIC SIGNATURE CORRELATES WITH THE GRADE OF STEATO... |
2016 |
| Details |
FRI-069 STEREOTACTIC ABLATIVE RADIOTHERAPY IN THE TREATMENT OF HEPATOCELLUL... |
2016 |
| Details |
SAT-040 THE LONG-TERM OUTCOME OF 154 PATIENTS RECEIVING BALLOON-OCCLUDED RE... |
2016 |
| Details |
T-CELL COMPARTMENTAFTER DAA-MEDIATED ANTIGEN REMOVAL... |
2016 |
| Details |
NETWORKS DELIVERS COMPARABLE PATIENT OUTCOMES... |
2016 |
| Details |
THU-442 POTENCY OF EXOSOMES FROM ADULT-DERIVED HUMAN LIVER STEM CELLS TO TR... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-070 HIGH EXPRESSION OF IL-17 AND ELEVATED HIGH-SENSITIVITY C- REACTIVE ... |
2016 |
| Details |
SAT-041 NON-SELECTIVE BETA BLOCKERS (NSBBS) USE IS ASSOCIATED WITH IMPROVED... |
2016 |
| Details |
VIRIN IN PATIENTS CO-INFECTED WITH HCVAND HIV: REAL-WORLD HETEROGENEOUS POP... |
2016 |
| Details |
PS140 THE FEASIBILITY OF BLOOD BORNE VIRUS TESTING IN INNER-CITY EMERGENCY ... |
2016 |
| Details |
THU-443 IDENTIFICATION OF A NEW INBORN ERROR IN THE PEROXISOMAL STEPS OF BI... |
2016 |
| Details |
THU-197 CALPROTECTIN AND MONOCYTE RESPONSES IN THE PATHOGENESIS OF VERTICAL... |
2016 |
| Details |
FRI-305 FUNCTIONAL HEPATIC VOLUME (FHV), PORTAL HYPERTENSION AND CIRRHOSIS ... |
2016 |
| Details |
FRI-071 TOLL-LIKE RECEPTOR 3: A POTENTIAL TUMOR SUPPRESSOR GENE IN HEPATOCE... |
2016 |
| Details |
SAT-042 MONITORING THE EFFECT OF LARGE VOLUME PARACENTHESIS ON SYSTEMIC HEM... |
2016 |
| Details |
SAT-135 HIGH EFFICACY AND FA VORABLE SAFETY OF ABT-493 AND ABT-530 CO-ADMIN... |
2016 |
| Details |
PS141 A NATIONWIDE SEROSURVEY OF HEPATITIS E VIRUS IN THE GENERAL POPULATIO... |
2016 |
| Details |
BY THE USE OF A NOVEL PANEL FOR GENETIC TESTING... |
2016 |
| Details |
THU-198 IN VITRO AND IN VIVO ANTIVIRAL ACTIVITIES OFAB-423 A POTENT SMALL M... |
2016 |
| Details |
FRI-306 LIVER AND SYSTEMIC IRON LOADING CHARACTERISE INITIAL DISEASE PROGRE... |
2016 |
| Details |
FRI-072 HEPATOCYTE-SPECIFIC SMAD7 DELETION ACCELERATES DEN INDUCED MOUSE HE... |
2016 |
| Details |
SAT-043 AQUAPORIN-2 IN CIRRHOSIS: RELATION TO DISEASE SEVERITY, MARKERS OF ... |
2016 |
| Details |
SAT-136 EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONA VIR AND DASAB... |
2016 |
| Details |
PS142 PILOT STUDY TO DETERMINE FEASIBILITY OF CONDUCTING HBV AND HCV ENTIRE... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-307 THE PREVALENCE OF NON-ALCOHOLIC STEATOHEPATITIS AMONG DIABETIC PATI... |
2016 |
| Details |
FRI-073 PROFILING OF INFILTRATING IMMUNE CELL IN TUMOR TISSUE OF HEPATOCELL... |
2016 |
| Details |
SAT-044 SAFETYAND EFFICACYOF EARLY INITIATION OF BETA BLOCKERS IN CIRRHOTIC... |
2016 |
| Details |
SAT-137 100% SVR4 AND FA VORABLE SAFETY OF ABT-493 + ABT-530 ADMINISTERED F... |
2016 |
| Details |
PS143 INTERVENTIONS AGAINST HCV & HIV INFECTIONS AMONG PEOPLE WHO INJECT DR... |
2016 |
| Details |
THU-446 COMPREHENSIVE PROTEOMIC STUDY OF HEPATOBLASTOMA: IDENTIFICATION OF ... |
2016 |
| Details |
THU-199 REPLICATION OF THE RNA GENOME OF HEPATITIS DELTAVIRUS (HDV) BY RNA ... |
2016 |
| Details |
FRI-308 THE ROLE OF SYSTEMIC INFLAMMATION AND ENDOTHELIAL DYSFUNCTION IN PA... |
2016 |
| Details |
INHIBITOR FOR HEPATOCELLULAR CARCINOMA... |
2016 |
| Details |
SAT-045 HEPATIC ENCEPHALOPATHY IN PATIENTS WITH NON-CIRRHOTIC PORTAL HYPERT... |
2016 |
| Details |
6 HCV- INFECTED PATIENTS WITH OR WITHOUT CIRRHOSIS... |
2016 |
| Details |
EPIDEMIOLOGICAL AND MODELLING INSIGHTS... |
2016 |
| Details |
THU-447 A PAIR OF BROTHERS WITH ACERULOPLASMINEMIA DUE TO A NOVEL NONSENSE ... |
2016 |
| Details |
THU-200 GENOMIC ANALYSES OF HOST-PATHOGEN INTERACTIONS IN CHRONIC HEPATITIS... |
2016 |
| Details |
FRI-309 NON-ALCOHOLIC STEATOHEPATITIS RESOLUTION IS ASSOCIATED WITH IMPROVE... |
2016 |
| Details |
FRI-075 A PANEL OF 3 MARKERS (H4K20ME2, H4K16AC AND PIVKA-II) FOR PREDICTIO... |
2016 |
| Details |
SAT-292 CAFFEINE AMELIORATES HIGH-FAT-DIET INDUCED NONNALCHOLIC STEATOHEPAT... |
2016 |
| Details |
SAT-139 HIGH EFFICACY OF AN 8-WEEK 3-DRUG REGIMEN OF GRAZOPREVIR/MK-8408/MK... |
2016 |
| Details |
LBO1 100% SVR4 WITH ABT-493 AND ABT-530 WITH OR WITHOUT RIBA VIRIN IN TREAT... |
2016 |
| Details |
THU-448 AUTOPHAGY IN TUMOR-FREE LIVERS AND HEPATOCELLULAR TUMORS IN A GLYCO... |
2016 |
| Details |
THU-201 APPLICATION OF MASS CYTOMETRY TIME OF FLIGHT (CYTOF) FOR SYSTEMATIC... |
2016 |
| Details |
FRI-310 EVALUATION OF EFFECTS OF CONCOMITANT MEDICATIONS FOR NON-ALCOHOLIC ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-293 DUAL PHOTON MICROSCOPY-BASED QUANTITATION OF FIBROSIS- RELATED COLL... |
2016 |
| Details |
SAT-140 EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND RIBA VIRIN FOR ELDERLY P... |
2016 |
| Details |
LBO2 NORURSODEOXYCHOLIC ACID IMPROVES CHOLESTASIS IN PRIMARY SCLEROSING CHO... |
2016 |
| Details |
THU-449 AA V INTEGRATION IN THE LIVER IN A MODEL OF INDUCED GENOTOXICITY... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-311 THE USE OF AN INULIN-TYPE PREBIOTIC IN NON-ALCOHOLIC STEATOHEPATITI... |
2016 |
| Details |
S EFFECT ON THE SECONDARY BILIARY CIRRHOSIS INDUCED BY LIGATION OF BILIARY ... |
2016 |
| Details |
SAT-294 SATURATED FATTY ACID, PALMITATE, INDUCED LIVER INFLAMMATION AND FIB... |
2016 |
| Details |
SAT-141 COST-EFFECTIVENESS OF ELBASVIR (EBR, MK-8742)/GRAZOPREVIR (GZR, MK-... |
2016 |
| Details |
Introduction:... |
2016 |
| Details |
THU-450 NEXT GENERATION SEQUENCING IN THE STUDY OF HYPERFERRITINEMIA... |
2016 |
| Details |
THU-202 CHRONIC HBV INFECTION DRIVES EXPANSION OF ADAPTIVE NK CELLS... |
2016 |
| Details |
FRI-312 THE ACCURACY OF TRANSIENT ELASTOGRAPHY AND COMPARISON OF NON-INVASI... |
2016 |
| Details |
FRI-077 MER TYROSINE KINASE POSITIVE TUMOUR ASSOCIATED MACROPHAGES ARE A NO... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-142 VIROLOGIC RESPONSE FOLLOWING ASUNAPREVIR/DACLATASVIR WITH OR WITHOU... |
2016 |
| Details |
LBO3 HIGH SUSTAINED VIROLOGICAL RESPONSE RATES USING GENERIC DIRECT ACTING ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-203 HEPATITIS B VIRUS ACTIVATES TOLL-LIKE RECEPTOR 2 SIGNALING UPON INF... |
2016 |
| Details |
FRI-313 THE SIGNIFICANT ASSOCIATION BETWEEN CONTROLLED ATTENUATION PARAMETE... |
2016 |
| Details |
FRI-078 THE POTENT PAN-CASPASE INHIBITOR IDN-7314 DOES NOTAFFECT TUMOR GROW... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-143 PREVALENCE AND MANAGEMENT OF DRUG-DRUG INTERACTIONS (DDIS) WITH OMB... |
2016 |
| Details |
LBO4 PROSPECTIVE RANDOMIZED CONTROLLED PHASE III TRIAL COMPARING THE EFFICA... |
2016 |
| Details |
GENETIC PREDISPOSITION AND ANTIBODIES, CONNECTING THE MISSING LINKS... |
2016 |
| Details |
THU-204 NUCLEIC ACID-BASED POLYMERS EFFECTIVE AGAINST HEPATITIS B VIRUS INF... |
2016 |
| Details |
FRI-314 SPLEEN DIMENSIONS EVALUATED BY ULTRASOUND ARE INVERSELY ASSOCIATED ... |
2016 |
| Details |
FRI-079 A HEPATIC STEM CELL VACCINE IS SUPERIOR TO AN EMBRYONIC STEM CELL V... |
2016 |
| Details |
SAT-295 COMPUTER ASSISTED MORPHOMETRIC ANALYSIS OF HEPATIC SONIC HEDGEHOG E... |
2016 |
| Details |
SAT-144 HIGH SVR RATES WITH SMV + SOF IN HCV GT1 AND GT4 PATIENTS WITH CIRR... |
2016 |
| Details |
Material and Methods:... |
2016 |
| Details |
THU-452 DEFECTIVE PLASMA MEMBRANE TARGETING OF P.I661T-ATP8B1, ASSOCIATED W... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-315 NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH AN EXCESSIVE C... |
2016 |
| Details |
FRI-080 GLOBAL ANALYSIS OF DNA METHYLATION IN HEPATOCELLULAR CARCINOMA BY A... |
2016 |
| Details |
SAT-296 PHOSPHOPROTEOMIC ANALYSIS OF INTRACELLULAR SIGNALING IN THE HUMAN H... |
2016 |
| Details |
SAT-145 CORE ANTIGEN QUANTIFICATION TO MONITOR TREATMENT EFFICACY IN PATIEN... |
2016 |
| Details |
18 IMPROVES CLINICAL PARAMETERS OF CIRRHOSIS IN PATIENTS WITH BASELINE MELD... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-205 MICRORNA-150 DOWNREGULATION IS INVOLVED IN PATHOGENESIS OF HBVASSOC... |
2016 |
| Details |
FRI-316 THE COMMON PROSTEATOTIC PNPLA3 (ADIPONUTRIN) P.I148M VARIANT MIGHT ... |
2016 |
| Details |
FRI-081 COEXPRESSION OF BTLA AND PD-1 IDENTIFIES A NOVEL CD4 T- CELL EXHAUS... |
2016 |
| Details |
SAT-297 HYPOXIA ACCELERATES FATTY ACID UPTAKE LEADING TO INCREASED FAT ACCU... |
2016 |
| Details |
SAT-146 HEPATITIS C CORE ANTIGEN ASSAY FOR THE MONITORING OF TREATMENT WITH... |
2016 |
| Details |
LBO6 NVR 3-778, A FIRST-IN-CLASS HBV CORE INHIBITOR, ALONE AND IN COMBINATI... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
THU-206 PRO-FIBROGENIC HOST PROTEIN OSTEOPONTIN PARTICIPATES IN HBV REPLICA... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-298 PERILIPINA IS A NOVEL BIOMARKER OF CIRCULATING ADIPOCYTE- DERIVED E... |
2016 |
| Details |
SAT-147 DASABUVIR AND OMBITASVIR/PARITAPREVIR/RITONA VIR WITH OR WITHOUT RI... |
2016 |
| Details |
LBO7 RANDOMIZED CONTROLLED TRIAL OF RIFAXIMIN VERSUS NORFLOXACIN FOR SECOND... |
2016 |
| Details |
THU-453 PELD SCORE AS A PROGNOSTIC FACTOR IN FULMINANT LIVER FAILURE CAUSED... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-299 INHIBITION OF PLASMINOGEN ACTIVATOR INHIBITOR 1 ATTENUATES DIET-IND... |
2016 |
| Details |
SAT-148 C-SWIFT RETREATMENT FINAL RESULTS: HIGHLY SUCCESSFUL RETREATMENT OF... |
2016 |
| Details |
LBO8 SIX WEEKS OF SOFOSBUVIR/LEDIPASVIR (SOF/LDV) ARE SUFFICIENT TO TREAT A... |
2016 |
| Details |
THU-454 ANALYSIS OF TREATMENTS FOR WILSON DISEASE USING PATIENT-SPECIFIC IN... |
2016 |
| Details |
THU-207 THE CGAS-STING PATHWAY EXHIBITS ANTIVIRAL ACTIVITY AGAINST HEPATITI... |
2016 |
| Details |
FRI-317 CHANGES OF THE GUT MICROBIOTA IN PATIENTS WITH OBESITY, METABOLIC S... |
2016 |
| Details |
FRI-082 NON-INVASIVE IN VIVO IMAGING OF HYPOXIA-INDUCIBLE FACTOR 1 FUNCTION... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-149 LEDIPASVIR/SOFOSBUVIR IN NS3/4A PROTEASE INHIBITOR- EXPERIENCED SUB... |
2016 |
| Details |
LBP500 SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRALS IN 2432 HCV PATIEN... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-208 A NEW MODEL FOR STUDYING INTERACTION BETWEEN HEPATITIS B VIRUS AND ... |
2016 |
| Details |
FRI-318 THE FTO RS1421085 T > C POLYMORPHISM IS ASSOCIATED WITH THE SEVERIT... |
2016 |
| Details |
FRI-083 DIFFERENTIAL MICRORNA EXPRESSION IN PLASMA MICROVESICLES PREDICT HE... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-150 HIGH EFFICACY OF INTERFERON-FREE TREATMENTS IN REAL- WORLD PATIENTS... |
2016 |
| Details |
LBP501 TNF MEDIATED LIVER DAMAGE IS PROTECTED BY RIPK1 IN HEPATITIS... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
: A BIOTOPE INCLUDING WNT SIGNALS, EXTRACELLULAR MATRIX REMODELING AND STEM... |
2016 |
| Details |
SAT-300 PRO-RESOLVING LIPID MEDIATORS MODULATE THE NLRP3 INFLAMMASOME IN CH... |
2016 |
| Details |
SAT-151 EFFICACY OF INTERFERON-FREE THERAPY IN CIRRHOTIC AND NON-CIRRHOTIC ... |
2016 |
| Details |
Material and Methods:... |
2016 |
| Details |
CAUSE OR EFFECT?... |
2016 |
| Details |
THU-209 LOCAL STIMULATION OF LSEC WITH NOD-LIKE RECEPTOR AGONISTS INDUCES T... |
2016 |
| Details |
FRI-319 PHYSICAL ACTIVITY REDUCE HEPATIC APOPTOSIS IN PATIENTS WITH NON-ALC... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-301 PRO-RESOLVING LIPID MEDIATORS MODULATE HYPOXIA- INDUCED AND LIPOTOX... |
2016 |
| Details |
SAT-152 SIMEPREVIR AND SOFOSBUVIR WITH OR WITHOUT RIBA VIRIN IN GENOTYPE 1 ... |
2016 |
| Details |
LBP502 APPLICABILITY, RELIABILITY AND DIAGNOSTIC PERFORMANCE OF FIBROSCAN F... |
2016 |
| Details |
THU-384 PORTAL HEMODYNAMICS PREDICTS THE OUTCOME IN SEVERE ALCOHOLIC HEPATI... |
2016 |
| Details |
THU-210 LSEC EXPRESS FUNCTIONAL NOD1 AND NOD2 RECEPTORS: A ROLE FOR NOD1 IN... |
2016 |
| Details |
FRI-320 EFFECTS OF OMEGA-3 POLYANSATURATED FATTY ACIDS AND METFORMIN ON NAS... |
2016 |
| Details |
FRI-085 TREATMENT OF CHOLANGIOCARCINOMA BY BROMELAIN AND PAPAIN... |
2016 |
| Details |
SAT-302 ADIPOSE TISSUE-LIVER AXIS: INVOLVEMENT OF THE TH17 PATHWAY IN THE P... |
2016 |
| Details |
SAT-153 INTRODUCTION OF DIRECTLY OBSERVED COMMUNITY PHARMACY DISPENSING OF ... |
2016 |
| Details |
LBP503 EFFECT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS ON SVR WITH THE 3D... |
2016 |
| Details |
THU-385 MIR-1224 IS UPREGULATED IN HEPATIC ISCHEMIA-REPERFUSION INJURY AND ... |
2016 |
| Details |
THU-211 HLA-DRB1*1501/1502 ALLELE PREDICTS SPONTANEOUS CLEARANCE OF HEPATIT... |
2016 |
| Details |
FRI-321 MATERNAL OBESITY AND DURATION OF BREASTFEEDING INFLUENCE THE RISKOF... |
2016 |
| Details |
FRI-086 NOTCH2 REGULATES SELF-RENEWAL AND TUMORIGENICITY OF HUMAN HEPATOCEL... |
2016 |
| Details |
SAT-303 IMPACT OF MITOCHONDRIAL UNCOUPLING ON HEPATIC METABOLISM AND NOVEL ... |
2016 |
| Details |
SAT-154 SOFOSBUVIR/LEDIPASVIR IN SPANISH PRISON POPULATION WITH CHRONIC HEP... |
2016 |
| Details |
LBP504 MONITORING THE WHO-RECOMMENDED CORE INDICATORS FOR VIRAL HEPATITIS B... |
2016 |
| Details |
THU-386 CLIF-C ALF SCORE IS A NEW PROGNOSTIC TOOLTO IDENTIFY LIVER TRANSPLA... |
2016 |
| Details |
THU-212 HEPATITIS B VIRUS INFECTION OF HUMAN STEM CELLS-DERIVED HEPATOCYTE-... |
2016 |
| Details |
FRI-322 CIRCULATING PCSK9 LEVELS ARE ASSOCIATED WITH THE HEPATIC FAT IN NON... |
2016 |
| Details |
FRI-087 BMI1 DRIVES MALIGNANT TRANSFORMATION OF HEPATIC PROGENITOR CELLS VI... |
2016 |
| Details |
SAT-304 A METABOLIC CIRCUITRY COMPRISING FREE FATTY ACIDS, MIR-122 AND TRIG... |
2016 |
| Details |
SAT-155 TREATMENT OF HCV GENOTYPE 2 WITH SOFOSBUVIR AND RIBA VIRIN RESULTS ... |
2016 |
| Details |
18 MONTH POST-TREATMENT FOLLOW-UP IN THE FRENCH ANRS CO22 HEPATHER COHORT ... |
2016 |
| Details |
THU-401 INCREASED TLR2 EXPRESSION IN PERIPHERAL CD4+T CELLS PROMOTES TH17 C... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-323 CLINICAL VALIDATION OF A NON-INVASIVE LIPIDOMIC TEST FOR THE DIAGNO... |
2016 |
| Details |
FRI-088 GENOTYPE-PHENOTYPE CORRELATION OF CTNNB1 MUTATIONS REVEALS DIFFEREN... |
2016 |
| Details |
SAT-305 HIGH-FAT DIET AND GLYCATION IMPAIR LIPID AND GLUCOSE METABOLISM REG... |
2016 |
| Details |
SAT-156 OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF P... |
2016 |
| Details |
LBP506 DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TR... |
2016 |
| Details |
THU-402 MAINTENANCE OF HEPATOCYTE PHENOTYPE IN VITRO: THE SINUSOIDAL MILIEU... |
2016 |
| Details |
THU-213 TREATMENT OF CHRONICALLY HBV-INFECTED CHIMPANZEES WITH RNA INTERFER... |
2016 |
| Details |
FRI-324 PNPLA3 VARIANTS CONFER AN INCREASED RISK OF ADVANCED FIBROSIS DUE T... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-306 ACID SPHINGOMYELINASE TARGETING REDUCES THE PROGRESSION OF DIET-IND... |
2016 |
| Details |
SAT-157 HIGH SVR RATES WITH THE COMBINATION OF ABT-493 + ABT-530 FOR 8 WEEK... |
2016 |
| Details |
LBP507 CO-ADMINISTRATION OF CHIMPANZEE ADENOVIRAL VECTORS OF DIFFERENT SERO... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-214 CONSISTENT SIMEPREVIR RESISTANCE PROFILE IN HEPATITIS C VIRUS GENOT... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-089 MOLECULAR HETEROGENEITYAND TRUNK DRIVER MUTATIONS IN HEPATOCELLULAR... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-158 FACTORS IMPACTING SVR12 FOR PATIENTS WITH ADVANCED CIRRHOSIS RECEIV... |
2016 |
| Details |
LBP508 METABOLIC PATHWAY REPROGRAMMING BY CRISPR/CAS9 GENOME EDITING... |
2016 |
| Details |
THU-403 INFLUENCE OF ACUTE FAILURE ON THE STRUCTURE OF GUT MICROBIOME IN PI... |
2016 |
| Details |
THU-215 DEEP SEQUENCING RESULTS FROM THE PHASE 2 IMPACT STUDY OF SIMEPREVIR... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-307 TUDCA PROTECTS AGAINST ENDOPLASMIC RETICULUM STRESS- INDUCED INFLAM... |
2016 |
| Details |
SAT-159 INTEGRATED ANALYSIS OF SOF + RBV OR LDV/SOF FOR THE TREATMENT OF GE... |
2016 |
| Details |
Introduction:... |
2016 |
| Details |
THU-404 EFFECTS OF HEALTHY- AND ACUTE LIVER FAILURE PLASMA ON DIFFERENTIATE... |
2016 |
| Details |
THU-216 RESISTANCE ANALYSIS IN 1284 PATIENTS WITH GENOTYPE 1 TO 6 HCV INFEC... |
2016 |
| Details |
FRI-325 QUANTIFICATION OF LIVER FAT CONTENT: DIAGNOSTIC EVALUATION OF PROTO... |
2016 |
| Details |
FRI-090 FUNCTIONAL GENOMICS ON TUMOR INVASION OF HUMAN HEPATOMA: A NOVEL TI... |
2016 |
| Details |
SAT-308 VITAMIN D3 TREATMENT IMPROVES LIVER HISTOLOGY AND HEPATIC GENE EXPR... |
2016 |
| Details |
SAT-160 SOFOSBUVIR PLUS SIMEPREVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIE... |
2016 |
| Details |
Material and Methods:... |
2016 |
| Details |
THU-405 ELEVATED LEVELS OF PROCALCITONIN DURING ACUTE LIVER FAILURE ARE NOT... |
2016 |
| Details |
THU-217 RETREATMENT OF HCV DAA FAILURES: HCV INFECTION MAY BE INCURABLE... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
LPHA IN LIVER CANCER CELLS THROUGH DIFFERENT MECHANISMS... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-161 FINAL RESULTS OF THE PYRAMID 1 STUDY, A PHASE 3 REGISTRATIONAL TRIA... |
2016 |
| Details |
A NORDIC POPULATION-BASED STUDY... |
2016 |
| Details |
THU-406 THE ROLE OF THE INFLAMMATORY RESPONSE IN NON-POD ALF: ARE SERIAL ME... |
2016 |
| Details |
THU-218 A VDLIB 2: NEWS DIRECT-ACTING ANTIVIRAL (DDA) IN HCV PATIENTS WITH ... |
2016 |
| Details |
FRI-326 A SYSTEMATIC REVIEW ON NON-INVASIVE DIAGNOSTIC METHODS FOR NON-ALCO... |
2016 |
| Details |
FRI-092 DICKKOPF-1 ENHANCES TUMOR ANGIOGENESIS AND ENDOTHELIAL MESENCHYMAL ... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-162 EFFECTIVENESS OF SIMEPREVIR TREATMENT FOR HEPATITIS C IN REAL PRACT... |
2016 |
| Details |
LBP510 ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF DIRECTACTING ANTIVIRAL T... |
2016 |
| Details |
THU-407 THE SCOTTISH LOOK BACK ON ACUTE LIVER FAILURE: ARE WE AS GOOD AS TH... |
2016 |
| Details |
THU-219 EFFICACY AND SAFETY OF IFN FREE, DIRECT-ACTING ANTIVIRAL- BASED TRE... |
2016 |
| Details |
NON-ALCOHOLIC FATTY LIVER DISEASE/NON-ALCOHOLIC STEATOHEPATITIS PATIENTS: I... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-309 LIVER REGENERATION CAPACITY AFTER PARTIAL HEPATECTOMY IN RATS WITH ... |
2016 |
| Details |
SAT-163 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WI... |
2016 |
| Details |
LBP511 EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/LEDIPASVIR TREATMENT FOR MONO... |
2016 |
| Details |
THU-408 INHIBITION OF CONNEXIN HEMICHANNELS ALLEVIATES ACETAMINOPHEN-INDUCE... |
2016 |
| Details |
THU-220 RESISTANCE ANALYSIS OF GENOTYPE 1 OR 3 HCV-INFECTED PATIENTS TREATE... |
2016 |
| Details |
FRI-328 ELEVATED MEAN PLATELET VOLUME IMPROVES CURRENT NON-INVASIVE MARKERS... |
2016 |
| Details |
FRI-093 A COSTIMULATION-ASSISTED PRIME-BOOST VACCINATION DRIVES POTENT IMMU... |
2016 |
| Details |
SAT-310 MODULATION OF INTESTINAL MICROBIOTA AND GUT-LIVER AXIS BY QUERCETIN... |
2016 |
| Details |
SAT-164 SOFOSBUVIR-BASED, RIBA VIRIN-FREE REGIMENS IN PATIENTS WITH CHRONIC... |
2016 |
| Details |
LBP512 EFFECTIVENESS AND SAFETY OF OMBITASVIR, PARITAPREVIR, RITONA VIR AND... |
2016 |
| Details |
THU-409 ANTI-INFLAMMATORY ACTION OF GLUTAMINE IN ACUTE LIVER FAILURE INDUCE... |
2016 |
| Details |
THU-221 HEPATITIS C VIRUS SCREENING PROJECT OF PATIENTS ON CURRENT ANTI-HCV... |
2016 |
| Details |
FRI-329 SERUM BILE ACID PROFILES ARE ASSOCIATED WITH HISTOLOGICAL SEVERITY ... |
2016 |
| Details |
FRI-094 RADIOFREQUENCYABLATION OF SOLID TUMORS IN COMBINATION WITH BORTEZOM... |
2016 |
| Details |
SAT-311 OBETICHOLIC ACID AMELIORATES NON-ALCOHOLIC FATTY LIVER DISEASE BY I... |
2016 |
| Details |
SAT-165 REAL-LIFE RESULTS OF SOFOSBUVIR BASED THERAPY FOR EGYPTIAN PATIENTS... |
2016 |
| Details |
LBP513 HIV COINFECTION IMPAIRS RESPONSE TO DAA-BASED HCV THERAPY... |
2016 |
| Details |
THU-410 HIGHER FERRITIN CONCENTRATIONS ARE ASSOCIATED WITH WORSE OUTCOME IN... |
2016 |
| Details |
THU-222 IN A 5-DAY MONOTHERAPY TRIAL, MK-8408 DEMONSTRATES POTENT ANTIVIRAL... |
2016 |
| Details |
FRI-330 IMPACT OF GWAS-IDENTIFIED COMMON VARIANTS ON HISTOPATHOLOGICAL FEAT... |
2016 |
| Details |
FRI-095 TRANSFORMING GROWTH FACTOR-BETA TRIGGERS TRANSENDOTHELIAL MIGRATION... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-166 OMBITASVIR/PARITAPREVIR/RITONA VIR WITH RIBA VIRIN ACHIEVES HIGH SU... |
2016 |
| Details |
LBP514 ANALYSIS OF THE IMPACT OF HIV CO-INFECTION ON HEPATITIS C TREATMENT ... |
2016 |
| Details |
THU-411 ESTABLISHING THE EDINBURGH MODEL: DOSE TO INJURY RESPONSE IN A LARG... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-331 RELATIONSHIP BETWEEN APPENDICULAR SARCOPENIA AND NON- ALCOHOLIC FAT... |
2016 |
| Details |
FRI-096 HEPATOCYTE-DERIVED OSTEOPONTIN PROMOTES THE DEVELOPMENT OF HEPATOCE... |
2016 |
| Details |
SAT-312 GENETIC AND HORMONAL CONTROL OF HEPATIC STEATOSIS IN FEMALE AND MAL... |
2016 |
| Details |
SAT-167 EFFECTIVENESS OF SIMEPREVIR-CONTAINING REGIMENS AMONG PATIENTS WITH... |
2016 |
| Details |
LBP515 PROSPECTIVE COMPARISON TO LIVER BIOPSY OF CONTROLLED ATTENUATION PAR... |
2016 |
| Details |
THU-412 MODULATION OF THE NON-CANONICAL NFKB PATHWAYS MAY UNDERLIE ALTERNAT... |
2016 |
| Details |
THU-223 NS3 GENETIC VARIABILITY IN HCV GENOTYPE 1A ISOLATES FROM LIVER TISS... |
2016 |
| Details |
FRI-332 FNDC5 RS3480 A > G POLYMORPHISM DISENTANGLES STEATOSIS FROM FIBROSI... |
2016 |
| Details |
FRI-097 IMPACT OF THE COMBINATION OF DIPEPTIDYL PEPTIDASE IV INHIBITOR AND ... |
2016 |
| Details |
SAT-313 EXPLORING NOVEL LINKS BETWEEN ANGIOGENESIS AND LIPID METABOLISM IN ... |
2016 |
| Details |
SAT-168 THE TOLERABILITY OF SOF/VEL FOR 12 WEEKS IN >1,000 PATIENTS TREATED... |
2016 |
| Details |
Material and Methods:... |
2016 |
| Details |
THU-414 ISCHEMIC POSTCONDITIONING (IPOSTC) PROTECTS HEALTHY AND FATTY RAT L... |
2016 |
| Details |
THU-224 GENOTYPIC AND PHENOTYPIC RESISTANCE IN CLINICAL SAMPLES SUBMITTED F... |
2016 |
| Details |
FRI-333 SARCOPENIA IS ASSOCIATED WITH SEVERE LIVER FIBROSIS IN PATIENTS WIT... |
2016 |
| Details |
FRI-098 GENOME-WIDE HIGH-THROUGHPUT SCREENING UNVEIL BIOMARKERS CORRELATED ... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-169 BASELINE CLINICAL AND LABORATORY PARAMETERS ASSOCIATED WITH CLINICA... |
2016 |
| Details |
LBP516 SIMEPREVIR PLUS SOFOSBUVIR FOR HEPATITIS C VIRUS GENOTYPE 4 INFECTIO... |
2016 |
| Details |
THU-415 IKKALPHA/BETA REGULATE HEPATOCARCINOGENESIS AND BILIARY HOMEOSTASIS... |
2016 |
| Details |
THU-225 C-EDGE CO-STAR: FA VORABLE IMPACT OF ELBASVIR AND GRAZOPREVIR ON HE... |
2016 |
| Details |
FRI-334 CIRCULATING CD36 CORRELATES WITH INTRAHEPATIC LIPID CONTENT IN NON-... |
2016 |
| Details |
FRI-099 ACTIVATION OF YAP-1 BY C-MYC PATHWAY IS A THERAPEUTIC TARGET IN HEP... |
2016 |
| Details |
SAT-314 GALECTIN-3 DEFICIENCY EXACERBATES LIVER STEATOSIS BUT PROTECTS FROM... |
2016 |
| Details |
SAT-170 COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C TREA... |
2016 |
| Details |
LBP517 ADD ON INTERFERON-ALPHA-2A FOR THE TREATMENT OF HBEAG NEGATIVE HEPAT... |
2016 |
| Details |
THU-416 SELECTIVE BLOCKADE OF METABOTROPIC GLUTAMATE RECEPTOR BY MPEP PROTE... |
2016 |
| Details |
THU-226 PAN-GENOTYPIC EVALUATION OF AL-335, A CLINICAL STAGE URIDINE ANALOG... |
2016 |
| Details |
FRI-335 CLINICAL DETERMINANTS OF FIBROSIS PROGRESSION IN AN ITALIAN PROSPEC... |
2016 |
| Details |
FRI-100 NEXT-GENERATION PROTEASOME INHIBITOR OPROZOMIB SYNERGIZES WITH MODU... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-171 HEPATITIS C TREATMENT AS PREVENTION: FOCUSING ON UNITED STATES PRIS... |
2016 |
| Details |
Material and Methods:... |
2016 |
| Details |
THU-417 ISCHEMIA/REPERFUSION INJURY IN THE AGED LIVER: THE IMPORTANCE OF TH... |
2016 |
| Details |
THU-227 DIRECT ANTIVIRAL COMBINATION TREATMENT ACCORDING TO PRESENCE OF BAS... |
2016 |
| Details |
FRI-336 SERUM LEVELS OF ENDOCANNABINOIDS ARE INDEPENDENT RISK FACTORS FOR N... |
2016 |
| Details |
FRI-101 THE UNFOLDED PROTEIN RESPONSE UNDERLIES MICROENVIRONMENTAL STRESS-I... |
2016 |
| Details |
SAT-315 LACK OF NLRP3-INFLAMMASOME LEADS TO GUT-LIVER AXIS DERANGEMENT AND ... |
2016 |
| Details |
SAT-172 A RETROSPECTIVE ANALYSIS OF HEPATITIS C INFECTED PATIENTS TREATED T... |
2016 |
| Details |
LBP518 HCV ERADICATION RESULTS IN REDUCTION OF HEPATIC VENOUS PRESSURE GRAD... |
2016 |
| Details |
THU-418 AMMONIA-INDUCED BRAIN OEDEMA AND IMMUNE DYSFUNCTION IS MEDIATED BY ... |
2016 |
| Details |
THU-228 AL-335, A ONCE-DAILY PANGENOTYPIC NUCLEOTIDE HCV POLYMERASE INHIBIT... |
2016 |
| Details |
FRI-337 SCREENING FOR LIVER DISEASE IN THE GENERAL POPULATION: THE POTENTIA... |
2016 |
| Details |
FRI-103 THE PRESENCE OF BCP/PC VARIANTS REDUCES THE RATE OF HBSAG LOSS AMON... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-173 SOF/VEL FOR 12 WEEKS IS WELLTOLERATED AND RESULTS IN HIGH SVR12 RAT... |
2016 |
| Details |
LBP519 NO EFFECT OF PROTON PUMP INHIBITOR (PPI) USE ON SVR WITH LEDIPASVIR/... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-229 ABT-493 AND ABT-530 COMBINATION DEMONSTRATED MINIMAL POTENTIAL FOR ... |
2016 |
| Details |
PNPLA3 NON-ALCOHOLIC FATTY LIVER DISEASE... |
2016 |
| Details |
FRI-104 PRECLINICAL CHARACTERIZATION OF POTENT CORE PROTEIN ASSEMBLY MODULA... |
2016 |
| Details |
SAT-316 A NUCLEAR MESSENGER LINKS CANNABINOID-1 (CB1) SIGNALLING TO FATTY L... |
2016 |
| Details |
SAT-174 ON-TREATMENT ILLICIT DRUG USE DID NOT IMPACT TREATMENT OUTCOME DURI... |
2016 |
| Details |
LBP520 IMPACT OF AETIOLOGY ON SURVIVAL AFTER SORAFENIB TREATMENT OF ADVANCE... |
2016 |
| Details |
THU-419 URINARY METABOLOMIC ANALYSIS OR EARLY PREDICTION OF SEPSIS IN ACUTE... |
2016 |
| Details |
THU-230 PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF NEXT GENERATION DIREC... |
2016 |
| Details |
FRI-339 RELATIONSHIP BETWEEN BASELINE HEPATIC DISEASE SEVERITY AND THE CARD... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-175 HCV GENOTYPE 3: META-ANALYSIS WITH A VAILABLE TREATMENT OPTIONS... |
2016 |
| Details |
LBP521 ADD-ON PEGINTERFERON ALFA-2A SIGNIFICANTLY REDUCES HBSAG LEVELS IN H... |
2016 |
| Details |
THU-420 THE IMPACT OF LIVER RESECTION ON BILE SALT AND FGF19 HOMEOSTASIS IN... |
2016 |
| Details |
THU-231 PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF NEXT GENERATION DIREC... |
2016 |
| Details |
FRI-340 EFFICACY OF GLUTATHIONE FOR THE TREATMENT OF NON- ALCOHOLIC FATTY L... |
2016 |
| Details |
FRI-105 UPDATE ON THE SAFETY AND EFFICACY OF REP 2139 MONOTHERAPYAND SUBSEQ... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
LBP522 DS102 - A BIOACTIVE LIPID FOR THE TREATMENT OF NASH... |
2016 |
| Details |
THU-421 THE FARNESOID-X-RECEPTOR AGONIST OBETICHOLIC ACID FURTHER INCREASES... |
2016 |
| Details |
THU-232 SEQUENCE ANALYSIS FOR RESISTANCE MONITORING FOLLOWING A SINGLE DOSE... |
2016 |
| Details |
FRI-341 NON-INVASIVE ASSESSMENT OF STEATOSIS AND LIVER FIBROSIS IN OVERWEIG... |
2016 |
| Details |
FRI-106 CIRCULATING IL-17 AND IP-10 AS POTENTIAL FACTORS TO INFLUENCE HBV I... |
2016 |
| Details |
SAT-318 PROTEIN KINASE STK25 CONTROLS LIPID PARTITIONING IN HUMAN HEPATOCYT... |
2016 |
| Details |
SAT-176 IMPACT OF BASAL COMORBIDITIES ON THE OVERALL BENEFIT OF DAA THERAPY... |
2016 |
| Details |
Conclusion:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
IMPROVES NON-ALCOHOLIC FATTY LIVER DISEASE... |
2016 |
| Details |
FRI-107 CLINICAL UTILITY OF HEPATITIS B CORE-RELATED ANTIGEN (HBCRAG) IN TH... |
2016 |
| Details |
SAT-319 PNPLA3 IS INVOLVED IN HEPATIC LIPIDS METABOLISM THROUGH XBP1 AND MO... |
2016 |
| Details |
SAT-177 REAL-WORD EFFECTIVENESS OF 8, 12 AND 24 WEEKS LEDIPASVIR (LDV)/SOFO... |
2016 |
| Details |
LBP523 EVIDENCE OF IMPRESSIVE REAL WORLD SVR FROM THE PORTUGUESE LEDIPASVIR... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
THU-233 SB 9200, A NOVEL AGONIST OF INNATE IMMUNITY, SHOWS POTENT ANTIVIRAL... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-108 NUCLEOSIDE ANALOGUES IMPROVE THE SHORT-TERM PROGNOSIS OF CHRONIC HE... |
2016 |
| Details |
SAT-321 EFFECT OF NUTRITIONAL WHEAT AMYLASE TRYPSIN INHIBITORS ON THE PROGR... |
2016 |
| Details |
SAT-178 LONG-TERM EFFECT OF THE PORTUGUESE UNIVERSAL ACCESS PROGRAM TO NEW ... |
2016 |
| Details |
LBP524 A NOVEL TASK SHIFTING MODEL TO EXPAND THE HCV CARE CONTINUUM: THE AS... |
2016 |
| Details |
THU-422 RESISTIN PREVENTS VISFATIN HEPATIC RECAPTATION FROM ADIPOSE TISSUE ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-343 LOW LEVELS OF NATURAL IGM ANTIBODIES TOWARDS OXIDATION- SPECIFIC EP... |
2016 |
| Details |
FRI-109 UGT2B28 GENOMIC VARIATION IS ASSOCIATED WITH HEPATITIS B E-ANTIGEN ... |
2016 |
| Details |
SAT-322 CHANGES IN LXR PHOSPHORYLATION ATTENUATE DIET-INDUCED LIVER INFLAMM... |
2016 |
| Details |
SAT-179 EFFICACY AND SAFETY OF HCV-TREATMENT WITH DIRECT-ACTING ANTIVIRAL A... |
2016 |
| Details |
LBP525 NOVEL THERAPEUTIC TARGETS FOR PRIMARY SCLEROSING CHOLANGITIS-ASSOCIA... |
2016 |
| Details |
THU-423 EVALUATION OF METABOLIC PARAMETERS OF HEPATIC DYSFUNCTION IN SUBJEC... |
2016 |
| Details |
THU-234 HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN PATIENTS INFECTED WITH G... |
2016 |
| Details |
FRI-355 NDI-010976, A POTENT, LIVER-DIRECTED, ORAL INHIBITOR OF ACETYL COA ... |
2016 |
| Details |
FRI-110 RANDOMIZED CONTROLLED TRIAL OF ENTECA VIR PROPHYLAXIS IN PATIENTS W... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-180 TREATMENT OF HEPATITIS C ASSOCIATED MIXED CRYOGLOBULINEMIA WITH DIR... |
2016 |
| Details |
LBP526 PREVALENCE OF RECTAL COLONIZATION BY MDR BACTERIA AND RELATIONSHIP W... |
2016 |
| Details |
THU-424 HMGB1 IN STEATOTIC AND NON-STEATOTIC LIVER TRANSPLANTATION FROM BRA... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-356 SARCOPENIA IS AN INDEPENDENT RISK FACTOR FOR BIOPSY- PROVEN NON-ALC... |
2016 |
| Details |
FRI-111 HEPATITIS DELTAVIRUS KINETICS UNDER THE PRENYLATION INHIBITOR LONAF... |
2016 |
| Details |
SAT-323 MIR-21 INHIBITION AND OBETICHOLIC ACID AMELIORATE NON- ALCOHOLIC ST... |
2016 |
| Details |
SAT-181 LARGE SINGLE CENTER EXPERIENCE OF SOFOSBUVIR AND LEDIPASVIR THERAPY... |
2016 |
| Details |
LBP527 SILYMARIN IMPROVES FIBROSIS IN NON-ALCOHOLIC STEATOHEPATITIS... |
2016 |
| Details |
THU-425 IMPAIRED LIVER REGENERATIVE RESPONSE FOLLOWING ADMINISTRATION OF AN... |
2016 |
| Details |
THU-235 PRE-TREATMENT REDUCTION IN SENSITIVITY TO SOFOSBUVIR AND RIBA VIRIN... |
2016 |
| Details |
FRI-357 THE CHARACTERISTICS OF NON-OBESE NON-ALCOHOLIC FATTY LIVER DISEASE:... |
2016 |
| Details |
FRI-112 MIR-B-INDEX: A CANDIDATE BIO-MARKER TO IDENTIFY THE IMMUNE CONTROL ... |
2016 |
| Details |
SAT-324 VITAMIN D RECEPTOR IS UP-REGULATED IN NAFLD HEPATOCYTES AND IS REQU... |
2016 |
| Details |
VIRIN) IN HCV GENOTYPE 1 TARGETING ADVANCED LIVER DISEASE (THE REV1TAL STUD... |
2016 |
| Details |
Introduction:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-236 CHARACTERIZATION OF THE ANTI-HCVACTIVITIES OF THE NEW CYCLOPHILIN I... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-113 TREATMENT DISCONTINUATION AFTER HBSAG LOSS IS SAFE IN CHRONIC HEPAT... |
2016 |
| Details |
SAT-325 ADAPTIVE IMMUNE RESPONSES PROMOTE LIVER FIBROGENIS DURING THE PROGR... |
2016 |
| Details |
SAT-183 LEDIPASVIR/SOFOSBUVIR WITH RIBA VIRIN FOR 12 WEEKS IS EFFECTIVE AND... |
2016 |
| Details |
LBP528 SUMO-SPECIFIC PROTEASE 3 IS AN IMPORTANT REGULATOR OF LIPID METABOLI... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
THU-237 PREVALENCE AND CHARACTERIZATION OF NS5A RESISTANCE ASSOCIATED VARIA... |
2016 |
| Details |
FRI-358 THE ECONOMIC AND CLINICAL BURDEN OF NON-ALCOHOLIC FATTY LIVER DISEA... |
2016 |
| Details |
FRI-114 NO BENEFICIAL OF LONG-TERM ANALOGUE TREATMENT ON THE CLINICALOUTCOM... |
2016 |
| Details |
AFFECTS FIBROGENIC PROGRESSION OF EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER D... |
2016 |
| Details |
SAT-184 DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBA VIRIN FOR THE TREA... |
2016 |
| Details |
Material and Methods:... |
2016 |
| Details |
THU-426 THE XENOGRAFT OF ADIPOSE DERIVED-HUMAN MESENCHYMAL STEM CELLS ATTEN... |
2016 |
| Details |
THU-238 NO TRANSMITTED RESISTANCE AGAINST HCV PROTEASE INHIBITORS IN ACUTE ... |
2016 |
| Details |
FRI-202 IMMUNE RESPONSE TO HEPATITIS B VACCINE BOOSTER IN ADOLESCENTS WHO R... |
2016 |
| Details |
FRI-115 PHARMACOKINETICS AND PHARMACODYNAMICS MODELING OF LONAFARNIB IN PAT... |
2016 |
| Details |
SAT-327 IDENTIFICATION OF MOLECULAR PATHWAYS FOR STEM CELL THERAPY OF NON-A... |
2016 |
| Details |
SAT-185 FAILURE WITH DAA REGIMENS IN A HIGH VOLUME TREATMENT CENTER UNDER R... |
2016 |
| Details |
THU-276 ASSESSING MECHANISMS OF KETOCONAZOLE AND AMIODARONE INDUCED STEATOH... |
2016 |
| Details |
THU-427 MELATONIN MITIGATES THE NUTRITIONAL AND MORPHOLOGICAL CHANGES OF RA... |
2016 |
| Details |
THU-239 RG-101 DEMONSTRATES FA VORABLE IN VITRO ANTIVIRAL ACTIVITY AND CROS... |
2016 |
| Details |
FRI-203 DONOR LIVER PERFUSATE NON-DOMINANT B CELL CHIMERISM CORRELATED WITH... |
2016 |
| Details |
FRI-116 USING OFF-TREATMENT HBV DNA LEVELS TO PREDICT ALT RELAPSE AFTER NUC... |
2016 |
| Details |
SAT-328 RELATIONSHIPS BETWEEN CHANGING GUT MICROBIOTA AND THE PATHOGENESIS ... |
2016 |
| Details |
SAT-186 HEPATIC FIBROSIS MEASURED BY ELASTOGRAPHYAMONG PEOPLE WHO INJECT DR... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-428 LIVER REGENERATION AFTER PARTIAL HEPATECTOMY IS SEVERELY ATTENUATED... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-204 T CELL-INDEPENDENT HEPATIC INFLAMMATION IN VIRAL- RELATED LIVER CIR... |
2016 |
| Details |
FRI-117 A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT POST- TREATMENT RESPO... |
2016 |
| Details |
SAT-329 PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE TOWARDS STEATOHEPA... |
2016 |
| Details |
SAT-187 REDUCING THE BURDEN OF HEPATOCELLULAR CARCINOMA IN JAPAN THROUGH TR... |
2016 |
| Details |
THU-277 A NOVEL IN VITRO TESTALLOWS CAUSALITYASSESSMENT OF DRUG INDUCED LIV... |
2016 |
| Details |
THU-036 HEPATOCELLULAR CARCINOMAS DIAGNOSED DURING SURVEILLANCE HA VE A BET... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-205 LONG-TERM EFFICACY OF RECOMBINANT HEPATITIS B VACCINATION ON PERSIS... |
2016 |
| Details |
FRI-118 TENOFOVIR DF MONOTHERAPY IS SUPERIOR TO ENTECA VIR- ADEFOVIR COMBIN... |
2016 |
| Details |
SAT-330 MITOCHONDRIAL ADAPTATION TO HIGH CALORIC CHALLENGE PROTECTS AGAINST... |
2016 |
| Details |
SAT-188 AN INTEGRATED SAFETYAND EFFICACYANALYSIS OF SOFOSBUVIR- BASED REGIM... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-037 ANALYSIS OF THE FREQUENCY AND RISK FACTORS ASSOCIATED WITH FAILURE ... |
2016 |
| Details |
THU-240 ANALYSIS OF HCV GENOTYPE 2 AND 3 VARIANTS IN PATIENTS TREATED WITH ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-119 FIVE-YEAR OUTCOME OF TELBIVUDINE VERSUS ENTECA VIR IN TREATING HIGH... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-189 SAFETY AND EFFICACY OF NEW DAA REGIMENS IN KIDNEY AND LIVER TRANSPL... |
2016 |
| Details |
THU-278 THE BILE ACID TAUROURSODEOXYCHOLIC ACID COOPERATES WITH N-ACETYLCYS... |
2016 |
| Details |
THU-038 COMPLETE RESPONSE UNDER SORAFENIB TREATMENT FOR HEPATOCELLULAR CARC... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-206 HIGH LEVELS OF IMMUNOGLOBULIN A ANTI-TISSUE TRANSGLUTAMINASE ANTIBO... |
2016 |
| Details |
FRI-120 ANTIVIRAL THERAPY FOR THE PREVENTION OF LONG-TERM CIRRHOSIS RISK IN... |
2016 |
| Details |
SAT-331 CAFESTOL BUT NOT RESVERATROL IS A PARTIAL AGONIST OF FARNESOIDX REC... |
2016 |
| Details |
SAT-190 RENAL FUNCTION DECLINE IS FREQUENT IN PATIENTS UNDERGOING HEPATITIS... |
2016 |
| Details |
THU-279 METHACETIN BREATH TEST IS SUPERIOR TO MELD IN PREDICTING MORTALITY ... |
2016 |
| Details |
THU-039 PROGNOSIS VALUE OF SKELETAL MUSCLE INDEX AND ALPHA FETOPROTEIN SCOR... |
2016 |
| Details |
THU-241 VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE... |
2016 |
| Details |
FRI-207 DIFFERENTIAL CONTRIBUTION OF PROGENITOR AND TERMINAL SUBSETS OF EXH... |
2016 |
| Details |
FRI-121 FIBROTIC BURDEN, NOTANTIVIRAL AGENT, DETERMINES CLINICAL OUTCOME IN... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-191 TREATMENT OF CHRONIC HEPATITIS C AFTER DECEASED DONOR RENAL TRANSPL... |
2016 |
| Details |
THU-280 INFECTION IS COMMON IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TRE... |
2016 |
| Details |
THU-040 CLINICAL FEATURES, DIAGNOSIS AND THERAPEUTIC ASSOCIATED OUTCOMES IN... |
2016 |
| Details |
INVOLVED IN THE DEVELOPMENT OF RA VS TOLERANT TO NS5A INHIBITORS IN PATIEN... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-122 ANALYSIS OF HEPATITIS B SURFACE ANTIGEN (HBSAG) LEVELS USING THE HI... |
2016 |
| Details |
SAT-332 THE INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN P62 INDUCES L... |
2016 |
| Details |
SAT-192 REAL-LIFE OUTCOMES OF 8 WEEKS REGIMEN OF SOFOSBUVIR AND LEDIPASVIR ... |
2016 |
| Details |
THU-281 ORAL TREATMENT WITH PBI-4425 DECREASES FIBROSIS IN CARBON TETRACHLO... |
2016 |
| Details |
THU-041 RISK FACTORS AND CHARACTERISTICS OF HEPATOCELLULAR CARCINOMA OCCURI... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-208 RETREATMENT OF SOFOSBUVIR-INCLUDING REGIMEN FAILURES IN THE REAL LI... |
2016 |
| Details |
FRI-123 OUTCOME OF 3-YEAR CONSOLIDATION THERAPY FOLLOWING HBEAG LOSS IN HBE... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-193 LOW SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN GENOTYPE (GT) 2 AND... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
THU-047 CIRCULATING TUMOR CELLS EARLY PREDICT PROGNOSIS OF HEPATOCELLULAR C... |
2016 |
| Details |
THU-243 ARISING OF SIMEPREVIR DRUG-RESISTANCE Q80K IN HEPATITIS C VIRUS SUB... |
2016 |
| Details |
FRI-209 THE GENERATION OF AN IMMUNOGENIC SECOND-GENERATION CONSERVED SEGMEN... |
2016 |
| Details |
FRI-124 EFFECTS OF ETV OR TDF ON RENAL FUNCTION IN PATIENTS WITH HBV-RELATE... |
2016 |
| Details |
IMPROVE STEATOHEPATITIS AND FIBROSIS SCORING IN A MOUSE MODEL OF NON-ALCOHO... |
2016 |
| Details |
SAT-194 SAFETY AND EFFICACY OF IFN- FREE ANTIVIRAL THERAPIES IN ADVANCED HC... |
2016 |
| Details |
THU-282 HISTOLOGICAL ACTIVITY AND FIBROSIS PREDICT LONG-TERM SURVIVAL IN PA... |
2016 |
| Details |
THU-048 LARGE SOLITARY HEPATOCELLULAR CARCINOMAS TREATED WITH TRANSARTERIAL... |
2016 |
| Details |
-ESTRADIOL IMPAIRS HCV INFECTION INTERFERING WITH VIRUS ASSEMBLY/RELEASE... |
2016 |
| Details |
FRI-210 NEUTROPHILS INDUCE EARLY HEPATOCYTE DEATH BY CONTACT DEPENDENT AND ... |
2016 |
| Details |
FRI-125 RANDOMIZED TRIAL OF TELBIVUDINE VERSUS ENTECA VIR IN REDUCING SERUM... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-195 SOF/VEL FOR 12 WEEKS RESULTS IN HIGH SVR12 RATES IN SUBJECTS WITH N... |
2016 |
| Details |
THU-283 MACROPHAGE ACTIVATION ASSESSED BY SOLUBLE CD163 AND SOLUBLE MANNOSE... |
2016 |
| Details |
THU-049 COMPARISON OF PROGNOSTIC SCORING SYSTEMS FOR PREDICTION OF SURVIVAL... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-211 T FOLLICULAR HELPER CELLS OF THE MOTHER PREVENT VERTICAL TRANSMISSI... |
2016 |
| Details |
FRI-126 PERSISTENCE TO ENTECA VIR TREATMENT FOR CHRONIC HEPATITIS B IN A RE... |
2016 |
| Details |
SAT-334 COMBINED ACTIVITY OF NTCP AND OATPS GOVERNS HEPATIC UPTAKE OF CONJU... |
2016 |
| Details |
SAT-196 OUTCOME, SAFETY AND TOLERABILITY OF TREATING HEPATITIS C IN DECOMPE... |
2016 |
| Details |
THU-284 AKKERMANSIA MUCINIPHILA PROTECTS FROM ALCOHOLIC LIVER DISEASE... |
2016 |
| Details |
THU-050 DIABETES IS NOT ASSOCIATED WITH AN INCREASED RISK OF HEPATOCELLULAR... |
2016 |
| Details |
THU-245 ANG2/ANG1 RATIO AS NON-INVASIVE BIOMARKER OF CIRRHOSIS IN PATIENTS ... |
2016 |
| Details |
FROM THE ANRS CO23 CUPILT STUDY... |
2016 |
| Details |
FRI-127 PHARMACOKINETICS AND SAFETY OF TENOFOVIR ALAFENAMIDE IN SUBJECTS WI... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-197 SAFETY AND TOLERABILITY OF RECURRENT HEPATITIS C TREATMENT IN POST ... |
2016 |
| Details |
THU-285 ADMINISTRATION OF BIFIDOBACTERIUM SP. LI09 OR BIFIDOBACTERIUM SP. L... |
2016 |
| Details |
THU-051 CLINICAL CHARACTERISTICS OF INTRAHEPATIC CHOLANGIOCARCINOMA IN SPAI... |
2016 |
| Details |
THU-246 NEUTRALIZING ACTIVITY OF MONOCLONAL ANTIBODIES DIRECTED AGAINST THE... |
2016 |
| Details |
FRI-213 LET-7A; A SINGLE MICRORNA WITH OPPOSING CELL-SPECIFIC- TUMORIGENIC ... |
2016 |
| Details |
FRI-128 TENOFOVIR VERSUS TENOFOVIR PLUS ENTECA VIR FOR CHRONIC HEPATITIS B ... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-198 PHARMACOKINETIC ANALYSES OF LEDIPASVIR/SOFOSBUVIR IN HCV-INFECTED S... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
IMMUNOLOGICAL DRIVERS OF HEPATOCELLULAR CARCINOMA PROGRESSION?... |
2016 |
| Details |
THU-247 CHRONIC HEPATITIS C IS ASSOCIATED WITH DYSBIOSIS OF THE SMALL INTES... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-129 ENTECA VIR VERSUS LAMIVUDINE FOR PREVENTION OF LIVER- RELATED EVENT... |
2016 |
| Details |
SAT-335 ROLE OF B-LYMPHOCYTES IN SUPPORTING ADAPTIVE IMMUNE RESPONSES ASSOC... |
2016 |
| Details |
SAT-199 ALL-ORAL TREATMENT WITH DACLATASVIR PLUS SOFOSBUVIR RIBA VIRIN IN ... |
2016 |
| Details |
THU-286 METABOLOMIC ANALYSIS OF THE DYNAMIC CHANGES OF FAECES IN THE ACUTE ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-248 FITNESS-ASSOCIATED MECHANISM OF DRUG RESISTANCE IN HEPATITIS C VIRU... |
2016 |
| Details |
1 T CELLS DIFFERENTIATE INTO CYTOTOXIC EFFECTOR CELLS IN CHRONIC VIRAL HEPA... |
2016 |
| Details |
CLINICAL OUTCOME... |
2016 |
| Details |
SAT-336 ANTIFIBROTIC EFFECTS OF COMBINED TREATMENT WITH FARNESOID X RECEPTO... |
2016 |
| Details |
SAT-200 INFLUENCE OF PROTON PUMP INHIBITORS AND H2 RECEPTOR ANTAGONISTS ON ... |
2016 |
| Details |
THU-287 CASPASE-8 DEFICIENCY AMELIORATES HEPATIC STEATOSIS, BUT NOT APOPTOS... |
2016 |
| Details |
THU-053 GALNT14 GENOTYPE PREDICTS PROGNOSIS OF MULTIPLE HEPATO- GASTROINTES... |
2016 |
| Details |
THU-249 IL-6/STAT3 PATHWAY UP-REGULATE MIR-125B EXPRESSION IN HEPATITIS C V... |
2016 |
| Details |
FRI-215 NOTCH SIGNAL REGULATES INFLAMMASOME NLRP3 ACTIVATION IN LIVER ISCHE... |
2016 |
| Details |
FRI-131 COST-EFFECTIVENESS ANALYSIS OF HEPATITIS B VIRUS SCREENING TO PREVE... |
2016 |
| Details |
SAT-337 DUODENAL-JEJUNAL BYPASS SURGERY ATTENUATES NONALCOHOLIC FATTY LIVER... |
2016 |
| Details |
SAT-201 RAPID CHANGES IN CHOLESTEROL IN CHRONIC HEPATITIS C PATIENTS TREATE... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-054 THE ROLE OF SERUM ALPHAFETOPROTEIN DETERMINATION IN HCV-CIRRHOSIS A... |
2016 |
| Details |
THU-250 EDP-494 IS A POTENT PAN-GENOTYPIC CYCLOPHILIN INHIBITOR FOR HCV INF... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-132 QUANTIFICATION OF SERUM HBSAG IS A USEFUL PARAMETER TO OPTIMIZE ANT... |
2016 |
| Details |
SAT-338 THREE-DIMENSIONAL HUMAN CELL CULTURE MODEL FOR STUDYING NON-ALCOHOL... |
2016 |
| Details |
SAT-202 IMPACT OF DAA THERAPY ON THE CANDIDACY TO LIVER TRANSPLANTATION AN ... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
THU-055 EFFECT OF LOCO-REGIONAL TREATMENT OF HEPATOCELLULAR CARCINOMA ON TH... |
2016 |
| Details |
THU-251 EPIGALLOCHATECHIN GALLATE STIMULATES THE EXPRESSION OF THE MIRNAS, ... |
2016 |
| Details |
FRI-216 DO MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS IMPACT FIBROSIS IN H... |
2016 |
| Details |
IN HBEAG-NEGATIVE CHRONIC HEPATITIS B... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-203 HIGH TOLERABILITY AND SUSTAINED VIROLOGIC RESPONSE WITH SOFOSBUVIR-... |
2016 |
| Details |
GS01 TREATMENT OF HEPATITIS C VIRUS IN PATIENTS WITH ADVANCED CIRRHOSIS: AL... |
2016 |
| Details |
THU-289 EXTRACELLULAR VESICLES AND THEIR MICRORNA CARGOS ARE NOVEL BIOMARKE... |
2016 |
| Details |
THU-056 DECREASING THE RISK OF HCC IN CAUCASIAN CHRONIC HEPATITIS B PATIENT... |
2016 |
| Details |
THU-252 SEQUENCING METHODS DEVELOPED FOR HEPATITIS C IDENTIFIES A NEW VIRUS... |
2016 |
| Details |
FRI-217 EFFICACY OF PROLONGED TENOFOVIR MONOTHERAPY FOR PARTIAL VIROLOGIC R... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-204 EFFICACY AND SAFETY OF DIRECT ACTING ANTIVIRAL THERAPY FOR HCV GENO... |
2016 |
| Details |
GS02 FIVE-YEAR ON-TREATMENT SYSTEMATICALLY MONITORING OF DYNAMIC CHANGES OF... |
2016 |
| Details |
THU-290 ACUTE ON CHRONIC LIVER FAILURE SECONDARY TO DRUGS: CAUSES, OUTCOME ... |
2016 |
| Details |
THU-057 THE VALIDATION OF A NEWLY UPDATED CHILD-TURCOTTE-PUGH SCORE USING I... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-218 THE INTERPLAY OF THE MAPKAP KINASES 2 AND 3 COORDINATES LPS-INDUCED... |
2016 |
| Details |
FRI-134 PREVIOUS INTERFERON TREATMENT FAILURE IS ASSOCIATED WITH AVERY LOW ... |
2016 |
| Details |
-CATENIN RESULTS IN EARLY LETHALITY DUE TO DISTURBANCES IN LIPID AND GLUCOS... |
2016 |
| Details |
SAT-205 REAL-LIFE EXPERIENCE OF DAA-BASED REGIMENS PLUS RIBA VIRIN IN CIRRH... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-292 INDEPENDENT AND ADDITIVE INDUCTION OF HEPCIDIN BY HYPOXIA AND H2O2:... |
2016 |
| Details |
THU-058 ADHERENCE TO GUIDELINES IN FIELD-PRACTICE: PROGETTO EPATOCARCINOMA ... |
2016 |
| Details |
THU-253 COMPARISON OF NEXT GENERATION SEQUENCING TECHNOLOGIES FOR THE COMPR... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-135 EFFICACY OF COMBINATION WITH INTERFERON AND NUCLEOS(T) IDE ANALOGUE... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-206 DIFFERENCES BETWEEN HEPATITIS HCV-MONOINFECTED AND HCV-HIV-COINFECT... |
2016 |
| Details |
GS03 A GENOME-WIDE ASSOCIATION STUDY IDENTIFIES PNPLA3 AND SLC38A4 AS RISK ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-059 EARLY EVALUATION OF ALPHA-FETOPROTEIN RESPONSE FOR PREDICTING OUTCO... |
2016 |
| Details |
THU-254 A SINGLE DOSE OF ANTI-MIR122 OLIGONUCLEOTIDE RG-101 RESULTS IN A LE... |
2016 |
| Details |
FRI-219 PREVENTION OF VIRAL SPREAD, VIREMIA REDUCTION AND HBSAG CLEARANCE I... |
2016 |
| Details |
FRI-136 COMPLETE BLOCKAGE OF HBV VIRUS REPLICATION AND INHIBITION OF CCCDNA... |
2016 |
| Details |
SAT-340 HEPATIC RESPONSE OF MAGNESIUM-RESTRICTION IN C57BL/6 MICE... |
2016 |
| Details |
SAT-207 EFFICACY AND TOLERABILITY OF INTERFERON-FREE ANTIVIRAL THERAPY IN K... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
THU-060 HCC DERIVED CIRCULATING MICROPARTICLES DETECT HEPATOCELLULAR CARCIN... |
2016 |
| Details |
THU-255 DIFFERENT PREVALENCE OF HCV RESISTANCE AND HCV RNA QUANTIFICATION W... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-137 EFFECTIVENESS OF PEGINTERFERON ALFA-2ATHERAPY IN HBEAG- POSITIVE AN... |
2016 |
| Details |
SAT-341 DIVERSE FUNCTIONAL ROLE OF LIVER DENDRITIC CELL SUBTYPES IN NON-ALC... |
2016 |
| Details |
SAT-208 TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 3 INFEC... |
2016 |
| Details |
GS04 THE MULTIKINASE INHIBITOR REGORAFENIB IMPROVES PORTAL HYPERTENSION IN ... |
2016 |
| Details |
THU-293 A METABO-TRANSCRIPTOMICS PAIRED ANALYSIS FOR IDENTIFICATION OF MOLE... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-256 GENETIC VARIABILITY OF AURORA B KINASE CODING REGION IN PATIENTS WI... |
2016 |
| Details |
FRI-220 TREATMENT OF HCV-RECURRENCE AFTER TRANSPLANTATION WITH SOFOSBUVIR/L... |
2016 |
| Details |
FRI-138 A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT RESPONSE AT 48 WEEKS ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-209 LEDIPASVIR/SOFOSBUVIR FOR RECURRENT HEPATITIS C IN LIVER TRANSPLANT... |
2016 |
| Details |
GS05 SAF SCORE AS A MARKER FOR MORTALITY IN NAFLD AFTER UP TO 41 YEARS OF F... |
2016 |
| Details |
THU-294 ROOM-TEMPERATURE SUSCEPTOMETRY ALLOWS THE SENSITIVE AND NON-INVASIV... |
2016 |
| Details |
THU-061 IN SITU ANALYSIS OF HTERT EXPRESSION IN ARCHIVAL HUMAN HEPATOCELLUL... |
2016 |
| Details |
THU-257 MIR135A-MEDIATED DOWNREGULATION OF PROTEIN-TYROSINE PHOSPHATASE DEL... |
2016 |
| Details |
FRI-221 IL-7 INDUCED TRAF1 UP-REGULATION RESTORES HCV-SPECIFIC CD8 T CELL R... |
2016 |
| Details |
FRI-139 AN EASY-TO-USE BASELINE SCORE TO PREDICT RESPONSE TO PEGINTERFERON ... |
2016 |
| Details |
SAT-342 COFFEE AND INTESTINAL PERMEABILITY IN A MICE MODEL OF NON-ALCOHOLIC... |
2016 |
| Details |
SAT-210 MODELING EARLY HCV KINETICS TO INDIVIDUALIZE DIRECT ACTING ANTIVIRA... |
2016 |
| Details |
GS06 A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOP... |
2016 |
| Details |
THU-295 GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) A SURROGATE MARKER OF END... |
2016 |
| Details |
A NATIONWIDE COHORT STUDY... |
2016 |
| Details |
THU-258 DAA-INDUCED HCV CLEARANCE DOES NOT RESTORE THE ALTERED CYTOKINE AND... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-140 INTERACTIONS STUDY OF NON- NUCLEOSIDE INHIBITORS WITH HEPATITIS B V... |
2016 |
| Details |
SAT-343 HEPATOCELLULAR AUTOPHAGY DEFICIENCY IN MICE MODULATES THE UNFOLDED ... |
2016 |
| Details |
SAT-211 EFFICACY OF DACLATASVIR/ASUNAPREVIR FOR PATIENTS WITH CHRONIC HEPAT... |
2016 |
| Details |
PS001 PREVALENCE AND CLINICAL IMPORTANCE OF HEPATITIS C VIRUS GENOTYPE 2 K/... |
2016 |
| Details |
THU-296 RIBOSOMAL PROTEIN GENES INCREASE THEIR OVERALL GENE EXPRESSION IN R... |
2016 |
| Details |
THU-063 NEUTROPHIL-LYMPHOCYTE RATIO CORRELATED WITH BCLC STAGING OF HCC PAT... |
2016 |
| Details |
THU-259 DETECTION OF THE NOVEL HUMAN PEGIVIRUS, HPGV-2, IN BLOOD... |
2016 |
| Details |
FRI-222 THE SODIUM TAUROCHOLATE CO-TRANSPORTING POLYPEPTIDE (NTCP) FACILITA... |
2016 |
| Details |
FRI-141 HIGH RATES OF SURFACE ANTIGEN LOSS AND SUSTAINED VIRAL SUPPRESSION ... |
2016 |
| Details |
SAT-055 PROGNOSTIC RELEVANCE OF STAGE MIGRATION IN PATIENTS WITH HEPATOCELL... |
2016 |
| Details |
SAT-212 SAFETY OF SIMEPREVIR-BASED TREATMENT FOR HEPATITIS C IN REAL PRACTI... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-297 ANALYSIS OF MOLECULAR MECHANISMS OF 5-FLUOROURACIL INDUCED STEATOSI... |
2016 |
| Details |
THU-064 DIFFERENTIAL CYTOKINE PROFILES IN PATIENTS WITH HEPATOCELLULAR CARC... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-223 NK CELLS FUNCTIONAL SKEW: IMPLICATIONS IN INNATE IMMUNITY TO HCV IN... |
2016 |
| Details |
FRI-142 THE ANALYSIS OF EFFICACY OF TENOFOVIR BASED-RESCUE THERAPY IN CHRON... |
2016 |
| Details |
SAT-058 HIGH-POWERED MICROWA VES ABLATION OF INTERMEDIATE HEPATOCELLULAR CA... |
2016 |
| Details |
SAT-213 INTERFERON-FREE TREATMENT WITH SOFOSBUVIR PLUS DACLATASVIR ACHIEVES... |
2016 |
| Details |
PS002 C-EDGE HEAD-TO-HEAD: EFFICACY AND SAFETY OF ELBASVIR AND GRAZOPREVIR ... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-065 AFRICAN AMERICANS WITH HEPATOCELLULAR CARCINOMA IN THE U.S. HA VE H... |
2016 |
| Details |
THU-260 APPLICABILITY OF DRIED BLOOD SAMPLES FOR HEPATITIS C VIRUS DETECTIO... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-143 ANTIVIRAL EFFICACY AND HOST IMMUNE RESPONSE INDUCTION WITH SB 9200,... |
2016 |
| Details |
SAT-059 ADHERENCE TO BCLC TREATMENT ALGORITHM AND SURVIVAL PREDICTORS IN SI... |
2016 |
| Details |
SAT-214 REAL WORLD EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR (LDV/ SOF) IN TRE... |
2016 |
| Details |
PS003 CYCLOPHILIN INHIBITORS REMODEL THE ENDOPLASMIC RETICULUM OF HCV-INFEC... |
2016 |
| Details |
THU-298 THE INFLUENCE OF CHEMOTHERAPY-ASSOCIATED LIVER INJURY ON OUTCOME AF... |
2016 |
| Details |
THU-066 INSURED PATIENTS WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES... |
2016 |
| Details |
A POTENT URIDINE-BASED NUCLEOTIDE POLYMERASE INHIBITOR IN PHASE I CLINICAL... |
2016 |
| Details |
FRI-224 SECRETORY LEUKOCYTE PROTEASE INHIBITOR DRIVES HEPATIC RESOLUTION RE... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-060 AN OBJECTIVE MODEL TO OPTIMIZE TREATMENT DECISIONS IN ADVANCED HEPA... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
PS004 THE REAL-WORLD ISRAELI EXPERIENCE OF TREATING CHRONIC HEPATITIS C, GE... |
2016 |
| Details |
THU-299 EVOLUTION OF PORTAL HEPATIC HEMODYNAMICS AND C-REACTIVE PROTEIN AT ... |
2016 |
| Details |
THU-067 THE IMPACT OF ETHNIC SUBGROUP ON TUMOR STAGE AT DIAGNOSIS, TREATMEN... |
2016 |
| Details |
THU-262 GENOME-TO-GENOME VIRUS-HOST ANALYSIS REVEALS HCV GENOTYPE 3 VIRAL P... |
2016 |
| Details |
FRI-225 HUMAN LIVER CD8+ T CELLS HA VE ATISSUE RESIDENT PHENOTYPE WHICH IS ... |
2016 |
| Details |
FRI-144 PREDICTING HBSAG CLEARANCE RESPONSES DURING ARC-520 RNA INTERFERENC... |
2016 |
| Details |
SAT-061 VITAMIN K1 PLUS SORAFENIB COMBINATION IS MORE EFFECTIVE THAN SORAFE... |
2016 |
| Details |
SAT-215 THE EFFECT OF SUSTAINED VIROLOGIC RESPONSE ON CEREBRAL METABOLISM A... |
2016 |
| Details |
PS005 THE EVOLUTION OF PORTAL PRESSURE AFTER VIRAL SUPPRESSION WITH INTERFE... |
2016 |
| Details |
THU-300 NUTRITIONAL, METABOLIC AND IMMUNOLOGICAL EFFECTS OF INTRA VENOUS LI... |
2016 |
| Details |
THU-068 THE EXTERNAL VALIDATION OF HONG KONG LIVER CANCER STAGING SYSTEM FO... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-226 HUMAN LIVER NK CELLS ARE PHENOTYPICALLY DIFFERENT FROM PERIPHERAL B... |
2016 |
| Details |
FRI-145 DELAYED SEROLOGIC RESPONSE IN MULTI-DRUG RESISTANT CHB PATIENTS WIT... |
2016 |
| Details |
SAT-062 PERCUTANEOUS RADIOFREQUENCY ABLATION VERSUS ETHANOL INJECTION IMPAC... |
2016 |
| Details |
EXPERIENCED U.S. VETERANS WITH GENOTYPE 1 HEPATITIS C INFECTION... |
2016 |
| Details |
PS006 HCV REINFECTION INCIDENCE AND OUTCOMES AMONG HIV INFECTED MSM IN WEST... |
2016 |
| Details |
THU-301 MCJ/DNAJC15, THE MITOCHONDRIAL FOE IN LIVER INJURY... |
2016 |
| Details |
THU-069 ROOM-TEMPERATURE SUSCEPTOMETRY DETECTS HEPATOCYTE BUT NOT MACROPHAG... |
2016 |
| Details |
THU-263 IN THE ERA OF NEW DIRECT ACTING ANTIVIRAL AGENTS HCV SEQUENCING ALL... |
2016 |
| Details |
FRI-227 CELLULAR NEUTROPHIL DYSFUNCTION IS A FEATURE OF EARLY CIRRHOSIS AND... |
2016 |
| Details |
FRI-147 LONG-TERM FOLLOW-UP OF EUROPEAN HBEAG-NEGATIVE CHRONIC HEPATITIS B-... |
2016 |
| Details |
SAT-071 SARCOPENIA AS A PROGNOSTIC FACTOR IN PATIENTS WITH EXTENSIVE FIBROS... |
2016 |
| Details |
SAT-217 SUSTAINED VIROLOGIC RESPONSE AMONG PATIENTS WITH GENOTYPE 1 HEPATIT... |
2016 |
| Details |
PS007 EUROPEAN RA VS DATABASE: FREQUENCY AND CHARACTERISTICS OF RA VS IN TR... |
2016 |
| Details |
THU-302 PREDICTING MORTALITY IN ALCOHOLIC HEPATITIS USING CLIF-ORGAN FAILUR... |
2016 |
| Details |
THU-070 VALIDATION OF THE GALAD SCORE FOR HEPATOCELLULAR CARCINOMA DIAGNOSI... |
2016 |
| Details |
THU-264 DISCOVERYOFA NOVEL HUMAN PEGIVIRUS IN BLOOD ASSOCIATED WITH HEPATIT... |
2016 |
| Details |
FRI-228 GENETICALLY ENGINEERING HBV-SPECIFIC CD8+ T CELLS RESISTANT TO TRAI... |
2016 |
| Details |
FRI-148 HBEAG SEROCONVERSION RATES AFTER FIVE YEARS OF FOLLOW- UP IN PATIEN... |
2016 |
| Details |
SAT-072 PROGNOSIS AFTER INTRAHEPATIC RECURRENCE IN THE PATIENTS WHO UNDERWE... |
2016 |
| Details |
SAT-218 PRIORITIZING TREATMENT CANDIDATES BY TIME DEGENERATIVE FACTORS IN P... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-303 THE MECHANISMS UNDERLYING MURINE AND HUMAN IBUPROFEN INTOXICATION... |
2016 |
| Details |
THU-071 VALIDATION OF MESIAH SCORE SYSTEM IN PATIENTS WITH HEPATOCELLULAR C... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-149 IL-33 CLEAR HEPATITIS B VIRUS IN HYDRODYNAMIC HBV MOUSE MODEL THROU... |
2016 |
| Details |
SAT-073 SAFETY AND EFFECTIVENESS OF SORAFENIB FOR THE TREATMENT OF HEPATOCE... |
2016 |
| Details |
SAT-219 TG-2349, A POTENT PROTEASE INHIBITOR, PLUS PEGIFN/RBV PROVIDES EXCE... |
2016 |
| Details |
PS008 HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN ... |
2016 |
| Details |
THU-304 NOVEL FUNCTION OF MITOCHONDRIAL LON PROTEASE (LONP) IN A DRUG-INDUC... |
2016 |
| Details |
THU-072 RACE DISPARITY IN CONDITIONAL SURVIVAL OF HEPATOCELLULAR CARCINOMA ... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-229 CAN PRE-CORE MUTATION STATUS HELP TO DETERMINE BETWEEN THE STAGE OF... |
2016 |
| Details |
FRI-150 MULTICENTER RANDOMIZED CONTROLLED TRIAL OF SWITCHING TO TENOFOVIR D... |
2016 |
| Details |
SAT-074 THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY FOR PORTAL VEIN TUMOR THRO... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
PS009 THE GUANYLYL CYCLASE STIMULATOR RIOCIGUAT REDUCES LIVER FIBROSIS AND ... |
2016 |
| Details |
THU-305 N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AND PROGNOSIS OF ALCOHOLIC... |
2016 |
| Details |
THU-073 MITOTIC CHECKPOINT CHK2 UPREGULATION IS LINKED TO CHROMOSOMAL INSTA... |
2016 |
| Details |
THU-265 DECIPHERING EPIGENETIC REPROGRAMMING IN PERSISTENT HEPATITIS C VIRU... |
2016 |
| Details |
FRI-230 OSTEOPONTIN PROMOTES CHOLANGIOCYTE CHEMOKINE SECRETION AND MACROPHA... |
2016 |
| Details |
FRI-151 SEQUENTIAL COMBINATION TREATMENT OF PEGYLATED INTERFERON CAN ACHIEV... |
2016 |
| Details |
SAT-075 REMNANT LIVER ISCHEMIA IS ASSOCIATED WITH EARLY RECURRENCE AND POOR... |
2016 |
| Details |
REAL-WORLD EXPERIENCE FROM QATAR... |
2016 |
| Details |
PS010 THE EFFECT OF TESTOSTERONE THERAPY ON MUSCLE MASS, BONE MASS AND HAEM... |
2016 |
| Details |
THU-306 HIGH FREQUENCY OF INFLAMMATORY CD16+ MONOCYTES IN ALCOHOLIC HEPATIT... |
2016 |
| Details |
THU-074 THE IMPACT OF SOCIO-ECONOMIC DEPRIVATION ON MANAGEMENT AND OUTCOMES... |
2016 |
| Details |
THU-266 DIMINISHED REPLICATION AND VIRAL COMPARTMENTALIZATION OF HEPATITIS ... |
2016 |
| Details |
FRI-231 HBV STRENGTHENS INTRAHEPATIC MYELOID-DERIVED CELLS MEDIATED T CELL ... |
2016 |
| Details |
FRI-152 SWITCHING TENOFOVIR DISOPROXIL FUMARATE (TDF) PLUS ENTECA VIR COMBI... |
2016 |
| Details |
SAT-076 RAMUCIRUMAB AS SECOND-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPA... |
2016 |
| Details |
SAT-221 A RISK FACTORS FOR DE NOVO DIABETES MELLITUS IN PATIENTS WITH CHRON... |
2016 |
| Details |
PS011 IN TOXIC CIRRHOTIC RATS, THE FXR AGONIST OBETICHOLIC ACID REDUCES LIV... |
2016 |
| Details |
THU-307 NATURAL KILLER CELLS MODULATE ENDOTHELIAL PROGENITOR CELLS IN ALCOH... |
2016 |
| Details |
A MULTICENTRE STUDY... |
2016 |
| Details |
THU-267 TRANSCRIPTOMIC ANTAGONISM BETWEEN HCV INFECTION AND VITAMIN D... |
2016 |
| Details |
FRI-232 KIR3DL1 IN COMBINATION WITH HLA-BW4-80T IS ASSOCIATED WITH SUPERIOR... |
2016 |
| Details |
-2A AND NUCLEOS(T)IDE ANALOGUES TREATMENTS IN HBEAG POSITIVE CHRONIC HEPATI... |
2016 |
| Details |
SAT-077 VALIDATION AND PERFORMANCE OF THE HONG KONG LIVER CANCER STAGING SY... |
2016 |
| Details |
SAT-222 THE OPTIMAL TIMING OF HEPATITIS C THERAPY IN TRANSPLANT ELIGIBLE PA... |
2016 |
| Details |
PS012 DIFFERENT PROBIOTIC STRAINS IN EXPERIMENTALLY INDUCED LIVER CIRRHOSIS... |
2016 |
| Details |
THU-309 EXPRESSION OF PRO-INFLAMMATORY AND HEPATOPROTECTIVE FACTORS AT EARL... |
2016 |
| Details |
THU-076 HEPATOCELLULAR CARCINOMA RESPONSE TO LOCAL REGIONAL THERAPY; CORREL... |
2016 |
| Details |
THU-268 CC-31244, A NOVEL, PAN-GENOTYPIC, POTENT NS5B NON- NUCLEOSIDE POLYM... |
2016 |
| Details |
FRI-233 MODULATIONS IN VITAMIN D RECEPTOR (VDR) EXPRESSIONS IN LATE FIBROSI... |
2016 |
| Details |
FRI-154 THE EFFICACY AND SAFETY OF TELBIVUDINE OR TENOFOVIR IN PREGNANCY FO... |
2016 |
| Details |
SAT-078 ORAL MEDICATIONS IMPROVE THE COMPLIANCE TO REGULAR SURVEILLANCE FOR... |
2016 |
| Details |
VIRIN AMONG HIV/HCV COINFECTED PATIENTS... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
THU-310 PREDNISOLONE PLUS S-ADENOSYLMETHIONINE IN SEVERE ALCOHOLIC HEPATITI... |
2016 |
| Details |
THU-077 PROGNOSTIC VALIDATION OF PROPOSED BCLC-B SUBSTAGING SYSTEM IN HEPAT... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-155 INCREASING INCIDENCE OF CANCER IN PERSONS LIVING WITH HIV COINFECTE... |
2016 |
| Details |
SAT-079 PERFORMANCE OF THE HAP SCORE AMONG PATIENTS WITH HEPATOCELLULAR CAR... |
2016 |
| Details |
SAT-224 EFFECTIVENESS OF DACLATASVIR BASED THERAPY IN PATIENTS WITH CHRONIC... |
2016 |
| Details |
PS014 HYPERTONIC SALINE VERSUS MANNITOL IN THE MANAGEMENT OF CEREBRAL EDEMA... |
2016 |
| Details |
THU-311 HEPATOTOXICITY ASSOCIATED WITH NON-STEROIDAL ANTI- INFLAMMATORY DRU... |
2016 |
| Details |
THU-078 METABOLIC DISORDERS ACROSS HEPATOCELLULAR CARCINOMA IN ITALY... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-234 INTERFERON SPARING DIRECTLY ACTING ANTIVIRAL (DAA) THERAPY FOR HCV ... |
2016 |
| Details |
FRI-156 STATIN USE IS ASSOCIATED WITH A LOWER RATE OF LIVER CANCER IN PATIE... |
2016 |
| Details |
SAT-080 HIGHER SERUM BILIRUBIN LEVELS OF LIVING LIVER DONORS MAY BE ASSOCIA... |
2016 |
| Details |
SAT-225 THE SAFETY AND EFFICACY OF DIRECT-ACTING ANTIVIRAL TREATMENT FOR PA... |
2016 |
| Details |
PS015 MER TYROSINE KINASE REGULATES THE ACTIVATION OF MYELOID CELLS AND INN... |
2016 |
| Details |
AN ANALYSIS OF 50,000 HOSPITAL ADMISSIONS... |
2016 |
| Details |
THU-079 VARIANTS ASSOCIATED WITH VITAMIN D METABOLISM AND PROGRESSION TO HE... |
2016 |
| Details |
THU-269 PREEXISTING HEPATITIS C VIRUS (HCV)-SPECIFIC CD8+ T CELLS ARE ABUND... |
2016 |
| Details |
FRI-235 VACCINE-INDUCED HCV-SPECIFIC CD8+ T CELL RESPONSE RESTRICTED BY THE... |
2016 |
| Details |
2015 IN ITALY: DATA FROM A PROSPECTIVE NATIONWIDE COHORT (ICONA)... |
2016 |
| Details |
SAT-081 PRIMARY PROPHYLAXIS FOR VARICEAL BLEEDING SHOULD BE DONE FOR PATIEN... |
2016 |
| Details |
SAT-226 LEDIPASVIR/SOFOSBUVIR THERAPY IS SAFE AND EFFECTIVE IN LIVER TRANSP... |
2016 |
| Details |
PS016 PORTAL VEIN THROMBOSIS RELEVANCE ON LIVER CIRRHOSIS: ITALIAN VENOUS T... |
2016 |
| Details |
THU-313 IMPACT OF HEPATITIS C VIRUS INFECTION IN THE LIVER-RELATED MORTALIT... |
2016 |
| Details |
THU-080 SURVIVAL IN PATIENTS WITH HEPATCELLULAR CARCINOMA AFTER TRANSARTERI... |
2016 |
| Details |
THU-270 MIR-146A-5P, A PROVIRAL FACTOR UP-REGULATED BY HEPATITIS C VIRUS IN... |
2016 |
| Details |
FRI-236 ROLE OF TYPE 2 INNATE LYMPHOID CELLS AND THE ALARMIN IL-33 IN A MOU... |
2016 |
| Details |
FRI-158 GENETIC AND METABOLIC FACTORS RELATED WITH INSULIN RESISTANCE IN CH... |
2016 |
| Details |
SAT-082 PERCUTANEOUS ELECTROCHEMOTHERAPY OF MALIGNANT MAIN PORTAL VEINS THR... |
2016 |
| Details |
SAT-227 LEDIPASVIR/SOFOSBUVIR FOR 8 WEEKS IN NON-CIRRHOTIC, TREATMENT NAIVE... |
2016 |
| Details |
PS017 COMPARISON OF DAILY NORFLOXACIN VERSUS WEEKLY CIPROFLOXACIN FOR THE P... |
2016 |
| Details |
THU-314 PREDICTING SHORT AND LONG-TERM MORTALITY OF HOSPITALIZED PORTUGUESE... |
2016 |
| Details |
THU-081 RISK OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS TR... |
2016 |
| Details |
THU-271 HEPATITIS C VIRUS CORE PROTEIN OF GENOTYPE 3A DOWNREGULATES PTEN EX... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-159 PATIENTS WITH CHRONIC HEPATITIS C CAN BE IDENTIFIED BY THEIR GUT MI... |
2016 |
| Details |
SAT-083 SHORT-TERM EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION WITH EPIRUBI... |
2016 |
| Details |
SAT-228 THE EFFECT OF SOFOSBUVIR CONTAINING REGIMES IN PATIENTS WITH HCV GE... |
2016 |
| Details |
PS018 SHOULD WE KEEP USING RIBA VIRIN TO TREAT HEPATITIS C RECURRENCE AFTER... |
2016 |
| Details |
THU-315 URINARY MICRO-ALBUMIN LEVEL AND ITS MODIFICATION STATUS SERVE AS AN... |
2016 |
| Details |
THU-082 ACCURACY OF THE RADIOLOGICAL DIAGNOSIS OF HEPATOCELLULAR CARCINOMA ... |
2016 |
| Details |
THU-272 REGULATION OF HEPATITIS C VIRUS INFECTION BY LONG NON-CODING RNA... |
2016 |
| Details |
FRI-237 RISK ASSESSMENT OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B ... |
2016 |
| Details |
FRI-160 RISKS OF LIVER COMPLICATIONS AFTER A LONG-TERM FOLLOW-UP IN PATIENT... |
2016 |
| Details |
SAT-084 PROGNOSTIC IMPACT OF INCIDENTAL HEPATOCELLULAR CARCINOMA AFTER LIVE... |
2016 |
| Details |
SAT-229 QUANTITIVE SYSTEMS PHARMACOLOGY MODEL OF HEPATITIS C: PREDICTION OF... |
2016 |
| Details |
PS019 A NOVEL INNATE IMMUNOTHERAPY AGAINST HCC VIA AUGMENTATION OF NK CELL ... |
2016 |
| Details |
THU-316 SYSTEMS LEVEL ANALYSIS FOR CHARACTERIZATION OF GENES RESPONSIBLE FO... |
2016 |
| Details |
A CASE SERIES... |
2016 |
| Details |
THU-273 ASUNAPREVIR EVOKES HEPATOCYTES INNATE IMMUNITY TO RESTRICT THE REPL... |
2016 |
| Details |
FRI-238 AN UNEXPECTED ROLE OF HIGH MOBILITY GROUP BOX 1 (HMGB1) AND NEUTROP... |
2016 |
| Details |
FRI-161 LONG-TERM ASSESSMENT OF RENAL FUNCTION IN PATIENTS FOLLOWING ANTIVI... |
2016 |
| Details |
SAT-085 OPTIMIZATION OF SURVIVAL PREDICTION IN PATIENTS UNDER SORAFENIB TRE... |
2016 |
| Details |
REAL LIFE DATA... |
2016 |
| Details |
EARLY OBSERVATIONS... |
2016 |
| Details |
THU-317 EFFECTS OF ALCOHOL ON TGF-BETA MEDIATED HEPATOCYTE APOPTOSIS... |
2016 |
| Details |
THU-084 ONLY ONE-THIRD OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WERE DIAGN... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-239 INTERFERON REGULATORY FACTOR 1 RESTRICTS HEPATITIS E VIRUS REPLICAT... |
2016 |
| Details |
FRI-162 EFFECT OF AMIODARONE AND HCV DIRECT-ACTING ANTIVIRAL AGENTS ON CARD... |
2016 |
| Details |
SAT-086 THE ACCURACY OF THE BASELINE PERIPHERAL LYMPHOCYTE VALUE IN PREDICT... |
2016 |
| Details |
SAT-231 SOFOSBUVIR/DACLATSA VIR/RIBA VIRIN FOR 12 WEEKS IN PATIENTS WITH GE... |
2016 |
| Details |
PS021 HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR/GS-9857 WITH OR WITHOUT RIBA ... |
2016 |
| Details |
THU-318 ASSOCIATIVE ROLE OF GENETIC ALTERATION IN ALCOHOL METABOLIZING GENE... |
2016 |
| Details |
THU-085 TUMOR-ASSOCIATED CIRCULATING MICROPARTICLES: A NOVEL CLINICAL TOOL ... |
2016 |
| Details |
THU-274 CONVERGENT TRANSCRIPTION OF INTERFERON-STIMULATED GENES BY TNF-A AN... |
2016 |
| Details |
B PATHWAYS... |
2016 |
| Details |
FRI-163 THE ADDITION OF RIBA VIRIN IS ASSOCIATED WITH A SIGNIFICANTLY REDUC... |
2016 |
| Details |
SAT-087 PREDICTION OF POST-OPERATIVE LIVER FAILURE IN CIRRHOTICS UNDERGOING... |
2016 |
| Details |
SAT-232 EFFICACY OF SOFOSBUVIR/LEDIPASVIR IN TREATING GENOTYPE 1 AND 4 HEPA... |
2016 |
| Details |
PS022 STATINS REDUCE ESOPHAGEAL VARICEAL BLEEDING IN CHRONIC HEPATITIS B PA... |
2016 |
| Details |
THU-319 MOLECULAR ELLIPTICITY OF CIRCULATING ALBUMIN-BILIRUBIN COMPLEX IS A... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-275 UNPHOSPHORYLATED ISGF3 DRIVES THE BASAL TRANSCRIPTION OF INTERFERON... |
2016 |
| Details |
FRI-241 MIR-155: A DOUBLE FACED MICRORNA WITH RESPECT TO ITS IMPACT ON TUMO... |
2016 |
| Details |
FRI-164 GLOMERULAR AND TUBULAR KIDNEY INVOLVEMENT IN HCV CHILD-A CIRRHOSIS... |
2016 |
| Details |
SAT-088 RESULTS OF RADIOFREQUENCY ABLATION IN A COHORT OF CIRRHOTIC PATIENT... |
2016 |
| Details |
SAT-233 DETERMINATION OF LEDIPASVIR CONCENTRATIONS IN PATIENTS WITH DECOMPE... |
2016 |
| Details |
PS023 PLPNA3 STATUS IN NASH IS ASSOCIATED WITH INCREASED HISTOLOGICAL SEVER... |
2016 |
| Details |
THU-320 IRREVERSIBLE MODIFICATION OF CIRCULATING ALBUMIN IN ACUTE ON CHRONI... |
2016 |
| Details |
THU-086 RACIAL AND ETHNIC DISPARITIES IN ETIOLOGY OF LIVER DISEASE, TUMOR C... |
2016 |
| Details |
MIRNA155 - SOCS1 PATHWAY IN PRIMARY BILIARY CIRRHOSIS... |
2016 |
| Details |
FRI-242 LIVER DERIVED MIR-122 MEDIATES INFLAMMATION-INDUCED ANEMIA BY TARGE... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
SAT-089 SEX DIFFERENCES IN DISEASE PRESENTATION, TREATMENT, AND CLINICAL OU... |
2016 |
| Details |
SAT-234 SOFOSBUVIR AND LEDIPASVIR VERSUS SOFOSBUVIR AND SIMEPREVIR COMBINAT... |
2016 |
| Details |
PS024 SOFOSBUVIR/VELPATASVIR IN COMBINATION WITH RIBA VIRIN FOR 24 WEEKS IS... |
2016 |
| Details |
THU-321 AN IMMUNE MODULATORY EFFECT BY ORAL CO-ADMINISTRATION OF SOY-DERIVE... |
2016 |
| Details |
THU-087 POPULATION-BASED FACTORS ASSOCIATED WITH EARLY DEATH AFTER LIVER CA... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-243 CYSTEINE CATHEPSINS ARE INVOLVED IN A DOUBLE CHECK-POINT DURING HEP... |
2016 |
| Details |
FRI-165 COBAS(R) HCV GT FOR USE ON THE COBAS(R) 4800 SYSTEM: A HIGHLY ACCUR... |
2016 |
| Details |
SAT-090 MULTIMODALITY TREATMENT OF HEPATOCELLULAR CARCINOMA: HOW FIELD PRAC... |
2016 |
| Details |
SLASH C TRIAL... |
2016 |
| Details |
PS025 HCV T CELL RE-VACCINATION STRATEGIES USING SIMIAN ADENO AND MVAVIRAL ... |
2016 |
| Details |
THU-322 PRIMARY LIVER INJURY AND DELAYED RESOLUTION OF LIVER STIFFNESS AFTE... |
2016 |
| Details |
THU-088 TIME-TRENDS IN INCIDENCE AND SURVIVAL OF HEPATOCELLULAR CARCINOMA I... |
2016 |
| Details |
IN PATIENTS WITH AUTOIMMUNE HEPATITIS ON IMMUNOSUPPRESSIVE TREATMENT... |
2016 |
| Details |
FRI-244 HEPATITIS B VIRUS X PROTEIN STIMULATES HBV REPLICATION THROUGH REGU... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-091 ALBI GRADE DETERMINES POST-PROGRESSION SURVIVALS AFTER SORAFENIB TR... |
2016 |
| Details |
SAT-236 SOFOSBUVIR, LEDIPASVIR IN IBD TREATED PATIENTS WITH ADVANCED BIOLOG... |
2016 |
| Details |
PS026 RNA INTERFERENCE MEDIATED SUPPRESSION OF HBV TRANSCRIPTS RESTORES HBV... |
2016 |
| Details |
THU-323 HEPCIDIN REGULATION IN PATIENTS WITH ALCOHOLIC LIVER DISEASE WITH I... |
2016 |
| Details |
THU-089 IMPACT OF SMOKING ON SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCI... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-245 FUNCTIONAL VARIANTS AND ABERRANT METHYLATION IN THE SOCS3 PROMOTER ... |
2016 |
| Details |
FRI-166 LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HCV INFECTION FOLLOWIN... |
2016 |
| Details |
SAT-092 MANAGEMENT OF HEPATIC EPITHELIOID HAEMANGIOENDOTHELIOMA: 5 YEAR SIN... |
2016 |
| Details |
SAT-237 OMBITASVIR (ABT 267), RITANA VIR BOOST WITH DASTASBUVIR (ABT 333) A... |
2016 |
| Details |
PS027 PRIMARY AND ADAPTIVE IMMUNE RESPONSE INVERSELY CORRELATE WITH ANTIGEN... |
2016 |
| Details |
THU-324 THE MITOCHONDRIAL CHOLESTEROL TRANSPORTER STARD1 PROMOTES CHRONIC A... |
2016 |
| Details |
THU-090 INCIDENTALLY DETECTED SPACE OCCUPYING LESIONS ON LIVER IMAGING IN C... |
2016 |
| Details |
FRI-346 BOTH BIOCHEMICAL HEPATITIS AND CHOLESTASIS AT SIX MONTHS AFTER LIVE... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
FRI-167 THE EFFECT OF RENAL OR HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS O... |
2016 |
| Details |
SAT-093 ANALYSIS OF THE EFFECTIVENESS OF SORAFENIB TAKING INTO ACCOUNT THE ... |
2016 |
| Details |
RESULTS FRO THE GERMAN HEPATITIS C COHORT (GECCO)... |
2016 |
| Details |
PS028 IL-2 THERAPY RESTORES THE IMPAIRED FUNCTION OF REGULATORY T CELLS IND... |
2016 |
| Details |
THU-001 BETA-BLOCKER USE IN HOSPITALIZED CIRRHOTIC PATIENTS WITH ASCITES IS... |
2016 |
| Details |
THU-091 VALIDATION OF CLINICAL SCORING SYSTEMS ARTAND ABCR AFTER TRANSARTER... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
FRI-168 DRUG-DRUG INTERACTION PROFILE OF SOFOSBUVIR/VELPATASVIR FIXED-DOSE ... |
2016 |
| Details |
SAT-094 VITAMIN C ENHANCES EPIGENETIC MODIFICATIONS INDUCED BY 5-AZACYTIDIN... |
2016 |
| Details |
6 INFECTION: RESULTS FROM THE SURVEYOR-I AND SURVEYOR-II STUDIES... |
2016 |
| Details |
PS029 TREM-2 PROTECTS THE LIVER FROM IMMUNE-MEDIATED HEPATOCELLULAR DAMAGE... |
2016 |
| Details |
THU-002 EFFICACY AND SAFETY OF SIMEPREVIR PLUS SOFOSBUVIR PLUS RIBA VIRIN F... |
2016 |
| Details |
THU-092 ALANINE AMINOTRANSFERASE NORMALIZATION DURING ENTECA VIR TREATMENT ... |
2016 |
| Details |
FRI-347 UTILITY OF UK-PBC RISK SCORES AS AN ALTERNATIVE TO TRANSIENT ELASTO... |
2016 |
| Details |
FRI-246 THE BREADTH OF CD8+ T CELL RESPONSES IN CHRONIC AND RESOLVED HEPATI... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-095 OUTCOMES OF PURE LAPAROSCOPIC VERSUS OPEN HEPATIC RESECTION FOR HEP... |
2016 |
| Details |
SAT-240 REAL-WORLD EFFECTIVENESS AND COST PER SUSTAINED VIRAL RESPONSE OF L... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
THU-003 CIRCULATING MICROPARTICLES AND RISK OF PORTAL VEIN THROMBOSIS IN PA... |
2016 |
| Details |
THU-093 FALSE-NEGATIVE LIVER ULTRASOUND LIMITS BENEFITS OF HCC SURVEILLANCE... |
2016 |
| Details |
FRI-348 CHOLESTASIS INDUCES EXPRESSION OF THE ONCOFETAL MARKER NOPE IN ADUL... |
2016 |
| Details |
FRI-247 IMPAIRED INDUCTION OF ACQUIRED IMMUNOLOGICAL TOLERANCE MAY PREDICT ... |
2016 |
| Details |
FRI-169 STEADY-STATE PHARMACOKINETICS OF SOFOSBUVIR AND VELPATASVIR IN HCV-... |
2016 |
| Details |
SAT-096 MICROWA VE ABLATION VERSUS RADIOFREQUENCYABLATION FOR HEPATOCELLULA... |
2016 |
| Details |
SAT-241 LEDIPASVIR/SOFOSBUVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAVE HCV G... |
2016 |
| Details |
PS030 PTX3 IS A NOVEL MARKER OF DISEASE PROGRESSION IN ALCOHOLIC HEPATITIS ... |
2016 |
| Details |
THU-004 WHOLE BLOOD COAGULATION TESTS ARE NOT EQUALLY ABLE TO DETECT HAEMOS... |
2016 |
| Details |
THU-094 EFFICACY AND SAFETY OF PERCUTANEOUS LASER ABLATION THERAPY FOR TREA... |
2016 |
| Details |
FRI-349 PRURITUS AND SERUM AUTOTAXIN IN PATIENTS WITH PRIMARY BILIARY CIRRH... |
2016 |
| Details |
FRI-248 EXPRESSION PROFILE OF MIR-183 AND MIR-191 IN ACUTE LIVER FAILURE... |
2016 |
| Details |
2014: THE HITS-P STUDY... |
2016 |
| Details |
SAT-097 TARGETED PROTEOMICS PREDICTS SUSTAINED COMPLETE RESPONSE AFTER TRAN... |
2016 |
| Details |
SAT-242 LEDIPASVIR/SOFOSBUVIR (LDV/SOF) FOR 8 WKS IN GENOTYPE 1 (GT1) TREAT... |
2016 |
| Details |
PS031 CHARACTERISATION OF THE SPECIFICITY, FUNCTIONALITY AND DURABILITY OF ... |
2016 |
| Details |
THU-005 SUSTAINED VIROLOGICAL RESPONSES (SVR) OF 97% IN GENOTYPE 2 (GT-2) P... |
2016 |
| Details |
THU-095 THE RISK FACTORS OF DEVELOPING HEPATOCELLULAR CARCINOMA IN PATIENTS... |
2016 |
| Details |
FRI-350 SERUM LYSYL OXIDASE-LIKE-2 (SLOXL2) LEVELS CORRELATE WITH DISEASE S... |
2016 |
| Details |
FRI-249 DISTINCT CELL-SPECIFIC TNFR1-SIGNALING DETERMINES LIVER DAMAGE IN E... |
2016 |
| Details |
FRI-171 NEXT-GENERATION SEQUENCING ANALYSIS OF NS5A AND NS5B MINOR RESISTAN... |
2016 |
| Details |
SAT-098 EVALUATION OF EFFICACY AND SAFETY OF PERCUTANEOUS ASPIRATION SCLERO... |
2016 |
| Details |
SAT-243 REAL-WORLD EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR 8 WEEKS CHRONIC H... |
2016 |
| Details |
PS032 IMMUNOTHERAPY USING T CELLS REDIRECTED AGAINST HBV RESULTS IN REDUCED... |
2016 |
| Details |
THU-006 SELECTIVE ENDOTHELIN-A BLOCKADE DECREASES PORTAL PRESSURE IN PATIEN... |
2016 |
| Details |
THU-096 GADOXETIC ACID DISODIUM-ENHANCED MRI COMBINED SURVEILLANCE IMPROVES... |
2016 |
| Details |
FRI-351 RELIABILITY OF COMPUTED TOMOGRAPHY IN DIFFERENTIATING TYPE 1 AUTOIM... |
2016 |
| Details |
FRI-250 RESTORING THE EXPRESSION OF ENDOGENOUS IGF-1 BY MIR-486 IN NK CELLS... |
2016 |
| Details |
FRI-172 NEXT GENERATION SEQUENCING FOR HCV GENOTYPING AND OPTIONAL IDENTIFI... |
2016 |
| Details |
SAT-099 THERAPEUTIC STRATEGIES IN THE REAL LIFE IN BCLC-C HEPATOCELLULAR CA... |
2016 |
| Details |
MODELLING ITS ROLE IN HCV TRANSMISSION AND THE IMPACT OF SCALED-UP HCV TRE... |
2016 |
| Details |
PS033 THE DECISION FOR LIVER TRANSPLANT IN ACUTE ON CHRONIC LIVER FAILURE (... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
THU-097 POSTABLATION DES-GAMMA-CARBOXY PROTHROMBIN: PREDICTION OF PROGNOSIS... |
2016 |
| Details |
FRI-352 EVALUATION AND PREDICTORS OF MORTALITY IN PATIENTS WITH LIVER ABSCE... |
2016 |
| Details |
FRI-251 MIR 450B IS AN INDEPENDENT PROGNOSTIC MARKER FOR ACUTE LIVER FAILUR... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
SAT-100 RESPONSE AT FIRST CHEMOEMBOLIZATION IS A ROBUST PREDICTOR OF FA VOR... |
2016 |
| Details |
SAT-245 LONG-TERM IMPACT OF RESPONSE TO INTERFERON-BASED THERAPY IN PATIENT... |
2016 |
| Details |
PS034 CTLA-4 IS A NEGATIVE REGULATOR OF T CELL ACTIVATION IN ACUTE LIVER FA... |
2016 |
| Details |
THU-007 HIGH LIPOPOLYSACCHARIDE BINDING PROTEIN LEVELS ARE RELATED TO INTER... |
2016 |
| Details |
THU-098 POPULATION-BASED CLINICAL COHORT ALLOWS MAPPING OF HEPATOCELLULAR C... |
2016 |
| Details |
FRI-353 BEZAFIBRATE ALLEVIATES PRURITUS AND DECREASES SPECIFIC CIRCULATING ... |
2016 |